Geographical Effects on Adult Sickle Cell Disease Treatments, Morbidity, and Mortality by Busbee, Paula
Walden University
ScholarWorks
Walden Dissertations and Doctoral Studies Walden Dissertations and Doctoral StudiesCollection
2016
Geographical Effects on Adult Sickle Cell Disease
Treatments, Morbidity, and Mortality
Paula Busbee
Walden University
Follow this and additional works at: https://scholarworks.waldenu.edu/dissertations
Part of the African American Studies Commons, and the Medicine and Health Sciences
Commons
This Dissertation is brought to you for free and open access by the Walden Dissertations and Doctoral Studies Collection at ScholarWorks. It has been



















has been found to be complete and satisfactory in all respects,  
and that any and all revisions required by  




Dr. Carla Riemersma, Committee Chairperson, Public Health Faculty 
Dr. Nicoletta Alexander, Committee Member, Public Health Faculty 






Chief Academic Officer 














Geographical Effects on Adult Sickle Cell Disease Treatments, Morbidity, and Mortality 
by 







Doctoral Study Submitted in Partial Fulfillment 
of the Requirements for the Degree of 









A small percentage of patients with sickle cell disease (SCD) have experienced an 
increase in life span by 10 years, while others with the same disease continue to die 
prematurely. The purpose of the study was to evaluate whether or not regional location 
was a barrier to care for adults with SCD in relation to emergency department visits and 
health outcomes at 16 and 21 years after the approval of hydroxyurea therapy as 
treatment. Secondary data were sourced and a retrospective quantitative correlational 
design was used to examine the effect of hydroxyurea treatment approval on emergency 
department visits and mortality (dependent variables) with changes in the regions for 
Northeast, Midwest, South, and West (independent variables). Insurance status, age, 
gender, and income level (covariables) were employed to describe the population. Chi-
Square analysis was used to examine the association of the variables and sample sizes 
provided by the HCUP datatsets; Nationwide Inpatient Sample (NIS) 2006 (n=67,214), 
NIS 2011 (n=80,040), Nationwide Emergency Department Sample (NEDS) 2006 
(n=164,698), and NEDS 2011 (n=215,296). The results of the analysis revealed a 
significant association between regional location, emergency department visits, and 
deaths among SCD patients. The implications for social change include improvements in 
health and health outcomes regionally, with adult SCD education for health care 
providers and patients on SCD treatment protocols. Adults with SCD might possibly 
benefit from this study with improvements in health and health outcomes for all regions 
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Chapter 1: Topic of the Study 
Introduction  
Sickle cell disease (SCD) is a genetic blood disorder affecting over 100,000 
African Americans in the United States and is one of more than 6,500 rare diseases in the 
United States recognized by the National Institute of Health (NIH) (Medline Plus: Rare 
Diseases, 2016). There is mandated newborn testing for SCD in the United States and the 
number of infants testing positive is over 500 annually (Addis, 2010). The 
pathophysiology of the disease involves the premature development of red blood cells, 
resulting in a sickle shape which causes occlusions as it flows through the small blood 
vessels. The results of the occlusions are known as vaso-occlusive crisis and hemolysis, 
which lead to severe pain in the joints, back, and anatomical areas of the body with major 
organs. The major organs that could be affected include the brain (stroke), spleen (splenic 
infarction), lungs (acute chest syndrome), penis (priapism), kidneys (kidney failure), and 
gallbladder (cholecystitis) (Addis, 2010). The most severe phenotypes of SCD are 
Thalassemia β 0 and HbSS; African Americans predominantly have the HbSS phenotype 
which has been associated with health complications and premature mortality (Serjeant, 
2013). 
 Of the more than 6,500 rare diseases, the Food and Drug Administration (FDA) 
has approved over 200 preventive drugs for treatment; hydroxyurea was the drug 
approved by the FDA in 1990 to treat SCD (Developing Products for Rare Diseases, 
2016). Improvements in treatment regimens have been credited with increasing the life 
span by 10 years for males and females; however only a small percentage of patients 
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have experienced the extended life span. Notably, there has been a 3% decrease in the 
mortality rate of children, which means that the adult population could increase placing 
more demands on the healthcare system for accessibility, quality care, and resources 
(Lanzrros, Carroll, & Haywood, 2013). Therefore, there is a need to evaluate the adult 
SCD population to identify barriers to care. Overcoming the barriers would be the next 
step for improving healthcare and outcomes for SCD.  
Not only is SCD detrimental to the health and lifestyle of the affected population, 
but there have been barriers to care identified for adults with sickle cell disease which 
contributes to the complications (Vallerand & Nowak, 2010). Research has shown that 
barriers to obtaining care would be insurance status and deficiencies in the number of 
physicians specializing (hematology) in the field (Bediako & Moffitt, 2011; Treadwell, 
Barreda, Kaur, & Gildengorin, 2015). The barriers to care when seeking medical care 
include lack of accessibility and stigmas (drug abuser, drug addict) attached to the disease 
(Voskaridou et al., 2010). 
This research study examined how the health of African American adults living 
with SCD could be affected according to residential region in the United States. High 
emergency department services usage, lack of accessibility to care, ineffective pain 
management and treatments (hydroxyurea use), and mortality rates could be indicators of 
regional barriers to care (Odesina et al., 2010). The social changes that could occur from 
the results of this study include the development of effective SCD transition programs, 




The transition programs from pediatric to adult care have not provided an 
environment for adults to receive the quality of care that was standard in the pediatric 
setting (DeBaum & Telfair, 2012). Additional potential social changes could be 
improvements in the quality-of-life, health outcomes, and life span with the provision of 
accessible and quality health care. Chapter 1 is a discussion of how living in different 
regions of United States could affect the health outcomes of adults with SCD. The 
literature review reiterated the impact of emergency visits, treatments, and mortality on 
the lives of patients with SCD.  
Background 
Emergency room services were used by 90% of adults with SCD for pain 
management and associated complications from organ damage (Ballas, Gupta, & Adams-
Graves, 2012; Brousseau, Owens, Mosso, Panepinto, & Steiner, 2010; Woods et al., 
1997). Adults have a higher usage of emergency services than children (Ballas et al., 
2012). The reasons for the high usage of emergency services would include lack of 
accessibility to care, ineffective pain management, and severity of disease (Haywood, 
Tanabe, Naik, Beach, & Lanzkron, 2013). The lack of accessibility to care and ineffective 
management of the disease occurred during the transition period from a child with SCD 
to an adult with SCD (Anderson, Bellot, Senu-Oke, & Ballas, 2014; DeBaum & Telfair, 
2012).  
Pain is the predominant symptom in sickle cell disease making pain management 
a priority focus for treatment regimens (Haywood et al. 2013). Three types of pain 
sensations have been identified in SCD; vaso-occlusive crisis (VOC), hemolysis, and 
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neuropathic pain (Smith, 2014). Vaso-occlusive crisis and hemolysis cause pain, damage 
to organs, and could lead to life-threatening complications and death (Booker, Blethyn, 
Wright, & Greenfield, 2006). Neuropathic pain is experienced in sickle cell disease 
patients with exposure to extreme temperatures such as hot and cold (Jones et al., 2005). 
The pain is described as numbness and tingling associated with a pins and needle type 
sensation (Ballas, 2007). The standard analgesic for severe pain management is opioids 
(Smith, 2014). Hemolysis and vaso-occlusive crisis should be managed using preventive 
treatments to improve decreasing the need for high doses of analgesics, major organ 
damage, and premature mortality (Voskaridou et al., 2010). The preventive treatment 
used in SCD is hydroxyurea which has been associated with decreased episodes of 
painful crisis, organ damage, and mortality rates (Colella et al., 2012; Smith et al., 2011). 
Overall, the use of preventive treatments and effective pain management are needed to 
improve the health of SCD patients.  
The lifespan of sickle cell patients is 43 years for males and 48 years for females 
(Tanabe et al., 2010). Complications of lung disease from organ damage have been 
shown to be the cause of death for 65% of adults with SCD (Lanzrros et al., 2013). 
Researchers have shown in a study from 1979 to 2005 that the median age of death in 
SCD males was 38 years and females were 42 years which was a decrease in the life span 
from 42 years for males and 48 years for females noted in 1990 (Lanzrros et al., 2013). 
According to Voskaridou et al. (2010) the lifespan of SCD patients has increased by 10 
years. The differences in research results could imply that the variations in life spans 
occur with changes in accessibility and treatment regimens in the various regions of the 
5 
 
United States. In this case, regional location in the United States could be a barrier to 
care. 
There was a gap in the literature that did not address the use of treatments and 
mortality in correlation to different geographic locations in the United States. Regional 
standards of care, accessibility, and physician performance in treating SCD have not been 
investigated as a possible barrier to care in SCD. The regional standards of care and 
physician performance could be examined using indicators which include use of 
emergency services (accessibility), changes in the number of emergency visits (disease 
management), and mortality rates in the years after the approval of hydroxyurea. The 
study was needed to identify significant barriers that could be corrected with appropriate 
resource allocation and SCD education. The lives of patients with SCD could improve 
physically and socially from the provision of quality care and improvements in health 
outcomes.  
Problem Statement 
There is high usage of emergency department services by adults with SCD which 
could be from the inability to secure the services of a private physician, inadequate pain 
management, and lack of a maintenance treatment regimen (Andermariam et al.,2014). 
The lack of hydroxyurea use among adult SCD patients has created a notable difference 
in outcomes when compared to the adult patients using hydroxyurea. Sickle cell patients 
using hydroxyurea as a routine treatment regimen could experience decreased painful 
episodes, minimal incidents of organ damage, and a longer life span by 10 years 
(Voskaridou et al., 2010). The problem lies in the need to identify and prevent barriers to 
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care that could hinder the use of hydroxyurea. According to Yawn et al. (2014), 
hydroxyurea use should be included as the standard of care for most patients with SCD. 
Included in the standards of care for SCD routine maintenance are an effective analgesic 
protocol, hydration, and hydroxyurea (Yawn et al., 2014). Thereby, with the acceptance 
of hydroxyurea by healthcare providers as a standard of care for SCD, a higher 
percentage of the population could benefit from the effects. 
 I designed this study to explore the effects of hydroxyurea approval for SCD 
treatment by the FDA, mortality rates (mortality), and accessible health care (emergency 
department utilization) in the four regions of the United States. The effects were 
examined using numerical data and statistical analysis in a quantitative correlational 
research design. Emergency visits were considered a predictor of disease management, 
severity of disease, and accessibility to care. Sickle cell patients require health services 
urgently due to the unpredictable onset of VOC not responding to the prescribed and 
recommended daily routine treatments (Tanabe et al., 2010). Studies (Davis, Gergen, & 
Moore, 1997; Telfair, Hague, Etienne, Tang, & Strasser, 2003) reported there were 
differences for SCD adults geographically in health service utilization, access to care, and 
pediatric mortality. McGann and Ware (2011) reported that hydroxyurea compliance was 
low in SCD patients even though a decrease in organ damage, episodes of painful crisis, 
and mortality has been associated with hydroxyurea use, which is approved by the FDA 
for SCD treatment. The physician not prescribing the drug and patient noncompliance 
with taking the drug were the reasons given for low usage of hydroxyurea (Smith et al., 
2011; Ware, 2010).  As a result, deficits in accessible resources and quality care 
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impacting the use of hydroxyurea could occur from a lack of sickle cell education and 
available physicians to provide care.  
Accessibility to health care resources and quality care has been shown to be a 
deficit for SCD patients that could contribute to a decreased quality-of-life and shortened 
life span. Sickle cell patients have a high use of emergency services and inpatient hospital 
services for pain management and treatment for complications from organ damage 
caused by manifestations of the disease along with increased healthcare costs (Brousseau 
et al., 2010; Wolfson, Schrager, Khanna, Coates, & Kipke, 2012). High inpatient 
hospitalization and emergency department visit rates for adults were associated with the 
use of government sponsored insurances and longer travel distances (Brousseau et al., 
2010; Wolfson et al., 2012). Private physicians that provide SCD quality care may not 
accept government sponsored insurances because of low payment fees, decreasing the 
availability of specialty care (Jan et al., 2013). Jan et al. (2013) published that for SCD 
young adults and adolescents the type of hospital and specialty of the provider were 
significant for improved health outcomes. The literature did not address how living in 
different geographical regions of the United States could affect resources, treatments, and 
mortality for sickle cell patients. 
Purpose of the Study 
A retrospective correlational quantitative design with secondary data was used to 
describe the relationship between regional geographical location and health outcomes 
from accessibility and treatments. The data was collected from 46 states and represent the 
four regions of the United States (Northeast, Midwest, South, and West). The data was 
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used to explore the effects of regional location (independent variable) on accessibility 
indicated by use of emergency services (dependent variable), disease management 
(dependent variable), and mortality rates (dependent variable) 16 and 21 years after 
hydroxyurea treatment was approved by the FDA. Improvements in treatment regimens 
could be indicated with decreased emergency service usage, increased use of 
hydroxyurea, and decreased mortality rates consistently in all regions.    
Research Questions and Hypotheses 
The information that was provided while responding to the hypotheses and 
research questions consisted of the effects of regional location on health care 
accessibility, treatment, and mortality. The number of emergency visits (accessibility), 
hydroxyurea approval and its effects 16 and 21 years postFDA approval on mortality 
rates and the number of emergency visits (disease management) were identified for each 
region. The information was used to answer how geographical location affects 
accessibility, health outcomes, and mortality of adults with sickle cell disease. The null 
and alternate hypotheses reflected whether there was a statistical significance for the 
association between accessibility, treatments, mortality, and geographical location of 
adults with SCD. 
RQ1: Is there a significant association between emergency services use 
(accessibility) among adults with SCD and regional geographic location (Northeast, 




H01: There is not a significant association between emergency services use 
(accessibility) and the regional geographical location (Northeast, Midwest, South, and 
West) represented by 46 states in the United States from the HCUP database in adults 
with SCD.  
Ha1: There is a significant association between emergency services use 
(accessibility) and the regional geographical location (Northeast, Midwest, South, and 
West) represented by 46 states in the United States from the HCUP database in adults 
with SCD.  
RQ2: Is there an association between the number of emergency department visits 
(disease management) for adults with SCD in the four regions (Northeast, Midwest, 
South, and West) 16 and 21 years after FDA approval of hydroxyurea for SCD 
treatment? 
H02: There is no significant association in the number of emergency department 
visits (disease management) for adults with SCD in the four regions (Northeast, Midwest, 
South, and West) 16 and 21 years after FDA approval of hydroxyurea for SCD treatment. 
Ha2: There is a significant association in the number of emergency department 
visits (disease management) for adults with SCD in the four regions (Northeast, Midwest, 
South, and West) 16 and 21 years after FDA approval of hydroxyurea for SCD treatment. 
RQ3: Is there an association between hydroxyurea approval and SCD mortality 
rates in adults in relation to geographic location (Northeast, Midwest, South, and West) in 
2006 (16 years later) and 2011 (21 years later)? 
10 
 
H03: Hydroxyurea approval does not have a significant association on mortality 
rates in adults with SCD in relation to geographic location (Northeast, Midwest, South, 
and West) in 2006 (16 years later) and 2011 (21 years later). 
Ha3: Hydroxyurea approval has a significant association on mortality rates in 
adults with SCD in relation to geographic location (Northeast, Midwest, South, and 
West) in 2006 (16 years later) and 2011 (21 years later). 
Theoretical and Conceptual Framework  
The socioecological model was used as the theoretical framework for the study 
along with data from Healthcare Cost and Utilization Project (HCUP) to determine the 
effects of internal and external factors that could be associated with sickle cell disease 
health outcomes; such as, the region where the patient lives, effect of FDA approval of 
hydroxyurea treatment for SCD, mortality, and geographical location to explain the 
differences in disease presentations among patients with the same genotype. The 
differences in outcomes recognized by the socioecological mode could encompass 
insurance status, income level, and availability of resources representative of local, state, 
and federal allocations. The history and additional information on the concepts for the 
socioecological model are discussed in Chapter 2. The concepts from the model were 
applicable to SCD level of knowledge in patients and physicians for preventive therapies. 
For example, patients with SCD should avoid extreme weather conditions and 
temperatures (hot, cold, and windy).  With the application of the concepts to SCD 
barriers to care, the quality of care in SCD could improve with increased knowledge, 
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along with health care and health outcomes. Even more, the utilization of health services 
and annual costs for treating SCD would likely decrease.  
The conceptual framework for the study was the Donabedian theory of quality 
care (DTQHC). Donabedian introduced the model in 1966 to evaluate and focus on 
health outcomes, treatments, and healthcare utilization (Kobayashi, Takemura, and 
Kanda, 2011). Descriptions were given for the three dimensions of quality health care in 
the last revision of the model in 1987: health, recipients of care, and providers of care 
(Kobayashi et al., 2011). It is important to realize that quality care is needed for sickle 
cell patients to improve their quality of life by decreasing incidents of comorbidities, 
provision of effective pain management, and decrease rates for premature mortality.  
Outcomes for the effects of the regional location (independent variable) were 
identified and evaluated using the concepts of the model with the examination of 
emergency visits (accessibility), effect of hydroxyurea treatment for SCD by the FDA on 
the mortality and emergency visits (disease management) [dependent variables]. 
Utilization of the model created an environment for identifying and evaluating outcomes 
and effects of the indicators. The Donabedian model is discussed with more detail in 
Chapter 2. The research question related to the quality healthcare framework was how 
does regional location could affect health outcomes, treatment, and mortality in adults 
with SCD? The documentation and knowledge that increased mortality, poor disease 
management, and increased emergency services usage could be indicators for the need of 
resources and education in SCD. Thereby, public officials on the state and federal levels 
could use the information to allocate resources for the care of SCD patients.  
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Nature of the Study 
A quantitative retrospective correlational method was used to obtain a numerical 
description of the population in order to describe the association between the variables to 
include regions, Northeast, Midwest, South, and West (independent variable), and the 
effect of FDA approval of hydroxyurea treatment on emergency visits and mortality 
(dependent variables) with statistical analysis. An examination of the variables regionally 
described whether the independent variable influenced the dependent variables and the 
correlation of emergency department use (accessibility), mortality rates, and emergency 
department visits (disease management) 16 and 21 years after hydroxyurea was approved 
for SCD treatment by the FDA. The datasets were obtained from HCUP; data for HCUP 
is collected and processed annually and sponsored by AHRQ (Agency for Healthcare 
Research and Quality, 2012). Two datasets represented in HCUP are the Nationwide 
Inpatient Sample (NIS) 2006 and 2011 and the Nationwide Emergency Department 
Sample (NEDS) 2006 and 2011 collected from 46 states representative of the four 
regions (Northeast, Midwest, South, and West) in the United States. The datasets were 
available from 2006 to 2013 and include information such as emergency room visits, 
diagnosis, geographical location, age, disposition, insurance status, and date of death. 
Definitions 
Acute chest syndrome: A diagnosis used in sickle cell disease when a combination 
of symptoms exists, such as fever, productive cough, difficulty breathing and decreased 
oxygen levels; along with a chest x-ray reading of acute infiltrate (Paul, Castro, 
Aggarwal, & Oneal, 2011). 
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Analgesic: a drug that relieves pain (Merriam-Webster’s Learner’s Dictionary, 
n.d.). 
Cholecystitis: inflammation of the gallbladder (Mayo Clinic, 1998-2016). 
HbSS: the most severe SCD phenotype which originates from inheriting two 
copies of the HbS mutation (Centers for Disease Control and Prevention, 2014). 
Hydroxyurea: a drug used to treat SCD by preventing the formation of sickle-
shaped red blood cells by stimulating the increased production of fetal hemoglobin 
(McGann & Ware, 2011, p. 2). 
Neuropathic: chronic pain caused by damage to nerves (Niscola, Sorrentino, 
Scaramucci, Fabtitiis, & Cianciulli, 2009, p. 470). 
Phenotypes: the genetic and epigenetic properties observed in an organism 
(Ballas, 2011, p. 512). 
Priapism: an involuntary long lasting penile erectile dysfunction (Azik et al., 
2012, p. 270). 
Splenic infarction: oxygen supply to the spleen is interrupted (Owusu-Ofori & 
Hirst, 2013, p. 3). 
Thalassemia β0: an inherited lifelong disease that is characteristically similar to 
SCD with milder symptoms (Serjeant, 2013, p. 2). 
Assumptions 
Assumptions that were made for this study included:  
• Adequate information from the NIS 2006, NIS 2011, NEDS 2006, and 
NEDS 2011 datasets to complete the study.  
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• A sufficient sample size to validate the study results. 
• Appropriate variances to determine associations and significance of 
regional location. 
• The study findings could be generalizable to adults (21 years and older) 
with SCD HbSS living in the United States.  
Scope and Delimitations 
Emergency visits were chosen for this study to indicate that there could be lack of 
accessibility to care from a private physician or comprehensive sickle cell disease 
facility. Severity of disease with ineffective pain management was an additional indicator 
for seeking care in the emergency department. The indicators for the effect of 
hydroxyurea (treatment) approval by the FDA 16 and 21 years later were the number of 
emergency visits and the mortality rates. Health care and health outcomes (mortality) 
were indicators of quality care which would be dependent on physician and patient SCD 
knowledge, along with effective pain management regimens to decrease episodes of VOC 
and hemolysis (analgesics and hydroxyurea); thereby decreasing organ damage and life 
threatening complications, and premature death.  
The population identified in this study were male and female adults (21 years and 
older) living in the United States with SCD HbSS. The International Classification of 
Diseases, Ninth Revision, Clinical Classification (ICD 9-CM) billing codes that were 
used for identification were 282.60 (nonspecific SCD), 282.61 (SCD without crisis), and 
282.62 (SCD with crisis). The codes were documented within the first five diagnoses 
fields of the medical record. The age group of the population represented adults that had 
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transcended from pediatric care to adult care and were confronted with adult barriers to 
care. Sickle cell disease HbSS has an occurrence of one in 300 to 500 African Americans 
and the phenotype is predominant in the race; Hispanics have an occurrence of one in 
36,000 for HbSS. Other less severe forms of SCD have been identified in people of 
Mediterranean and Asian descent. Specifically, the barriers to care for adults with SCD 
HbSS should be examined and provisions made to improve quality of care.  
The Health Belief Model (HBM) was not used as a theoretical framework in the 
study. The focus of the study was the identification of external barriers to care and the 
effects from lack of resources and knowledge. The concepts of the HBM focus on patient 
disease knowledge, reasons to control and prevent illness, perceptions of the illness, self-
efficacy, considerations for barriers and benefits to care, and self-care management 
(Glanz, Rimer, & Viswanath, 2008). Statements made pertaining to the results of the 
study were generalizable to adults (21 years and older) with SCD HbSS living in the 
United States.  
Limitations 
The results of the study are limited to the relationship and correlation of the 
independent variables (regions) and dependent variables (number of emergency visits and 
mortality rates 16 and 21 years after hydroxyurea approval). Covariates for external 
validity (gender, insurance status, and income level) for emergency visits and mortality 
were used to describe the population demographically. Internal validity for accuracy of 
information on number of emergency visits, mortality rates, and geographical location 




Factors affecting the health outcomes of SCD patients could be identified in this 
study, such as quality of care, premature death, and accessibility to care. Regional 
locations that could be lacking in resources and knowledge were identified by increased 
use of emergency services and mortality rates which could be representative of the lack 
of accessibility and low rates of hydroxyurea treatment after approval by the FDA. Health 
outcomes could be improved with the insight provided from the study results; 
justification would be provided for resource allocation to deficient areas and educational 
needs of healthcare professionals and patients. Social change could potentially be 
implicated with the use of SCD standardized treatment protocols to equalize medical 
treatment of SCD patients, identifying and recommending ways to increase accessibility 
to care, and to determine healthcare needs for resource allocation.  
Sickle cell disease treatment standards were developed by the World Health 
Organization in 1984 (revised in 2012), and the NIH: National Heart Lung and Blood 
Institute in 1984 (revised 2002) for the improvement of pain management and health 
outcomes (Moussavou, Vierin, Eloundou-Orima, Mboussou, & Keita, 2004). 
Manifestations of SCD impose symptoms and complications on the patients that require 
frequent inpatient hospital admissions and a high use of emergency services which 
increases health care expenditures. It was published in studies by (Brousseau et al., 2010; 
Wolfson et al., 2012) that long travel times to obtain medical care and the use of 
government issued insurance plans (Medicaid, Medicare) by adults with SCD were 
associated with increased inpatient hospitalizations and high emergency department 
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visits. At the same time, increased use of emergency services use could be directly related 
to the inability of SCD patients to obtain a private physician that will accept the lower 
fees paid by government issued insurances.  The costs of healthcare incurred by adults 
with SCD were reported by Woods et al., (1997) over a 2 year time frame to be $59 
million with government issued insurance plans used by two-thirds of the patients. The 
estimated costs of SCD health care expenditures for emergency visits and inpatient 
admits was reported in several studies (Andemariam et al., 2014; Epstein, Yuen, Riggio, 
Ballas, & Moleski, 2006) as $2.4 billion in 2006 with pain management as the underlying 
complaint. Adults with SCD have increased medical expenses when compared to children 
with SCD. A study was published by Kauf, Coates, Huazhi, Mody-Patel, and Hartzema 
(2009) showing the monthly costs for adult (50 to 64 years) SCD healthcare was $1382 
and children (0 to 9 years) was $892. The costs of healthcare for SCD patients are 
increasing because the patients are living longer. The burden of increasing medical 
expenses could be decreased with the implementation of effective pain management and 
treatment regimens which would be reflected in a reduction in inpatient hospital 
admissions and emergency department visits. For the most part, sickle cell patients could 
benefit from the use of standardized protocols throughout the United States to improve 
health outcomes and equalize the use of evidence-based treatments.  
Summary 
Chapter 1 provided an introduction to the pathophysiology of SCD, complications 
of the disease, barriers to care, and health outcomes. The problem statement addressed 
the focus of the study and directed the design of the study and research questions. 
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Assumptions and limitations were discussed along with the theoretical and conceptual 
frameworks using the concepts to improve the quality of care and identify the barriers to 
care. The knowledge gap was identified for regional location to be evaluated as barrier to 
care and the correlation of emergency visits and how FDA approval of hydroxyurea for 
SCD treatment could affect emergency visits and mortality rates.  
Chapter 2 contains the literature review which is sectioned by the prevailing 
themes found in the literature; emergency visits, pain management, treatments, 
complications, and mortality. Barriers to care were identified for many areas including 
insurance status, location (rural versus urban), lack of accessibility, income level, and 
stigmas. Geographical regions in the United States had not been evaluated as a barrier to 
care, which could affect emergency visits, treatment, and mortality rates in the reviewed 






Chapter 2: Literature Review 
Introduction 
Sickle cell disease HbSS is the most common phenotype among people of African 
descent and the population group for this research (Public Health of Oregon, 2010). 
Sickle cell HbSS phenotype is the most serious form causing pain from vaso-occlusive 
crisis and hemolysis, which in turn would be responsible for damage to major organs, life 
threatening complications, and mortality (Khoury, Musallam, Mroueh, & Abboud, 2011). 
People with sickle cell HbSC, Hb Sβ0 and Hb Sβ+ could present with mild to moderate 
symptoms similar to HbSS (Serjeant, 2013).  
Pain management, hydroxyurea, and blood transfusions use in SCD have shown 
positive effects for decreasing frequency of painful episodes, organ damage, and 
increased lifespan (Voskaridou et al., 2010). The problem would be the lack of the 
identification of barriers to care, which could result in decreased SCD comorbidities and 
increased life span for a greater number of SCD patients. It has been published that 
physicians are hesitant to prescribe hydroxyurea and have been found not to be up to date 
on sickle cell disease and treatment regimens (Smith et al., 2011; Ware, 2010). In 
addition, patients lack education on sickle cell disease, the treatments, and are not 
compliant with prescribed medications, such as hydroxyurea (Okam, Shaykevich, Ebert, 
Zaslavsky, and Ayanian, 2014).  The literature did not identify how geographical location 
in the United States affected treatments and mortality of patients with sickle cell disease 
creating a gap in the exploration of barriers to care.  
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The purpose of this study was to explore the four regions of the United States for 
SCD emergency visits, the effect of FDA approval of hydroxyurea for SCD treatment on 
the number of emergency visits, and mortality for the years 2006 (16 years later) and 
2011 (21 years later). The number of emergency visits phenomenally described a need to 
improve the management of SCD; the need for pain management and complications, 
provider performance in prescribing hydroxyurea, blood transfusions, and prophylactic 
blood transfusions. Patient compliance with hydroxyurea could indicate accessibility, and 
complications could be indicative of disease severity and the need for quality health care.  
The literature reviews on SCD focused on research in regards to treatment and 
mortality variations according to geographical location. Topics reviewed and included in 
Chapter 2 were resource utilization, standard and evidence based treatments, morbidity, 
and mortality with emphasis on geographical location to assess treatments and outcomes. 
The effect of geographical locations examined in North Carolina and California 
showed significant factors for high use of emergency services were by adults seeking 
pain management, further distance to access care, and holders of government issued 
insurance coverage (Hague & Telfair, 2000; Wolfson et al., 2012). Brousseau et al. 
(2010) published a retrospective study of eight states representing each region that have 
33% of the SCD population in the United States. The study using HCUP data concluded 
there were high rates of acute care and return visits for the sickle cell population 
(Brousseau et al., 2010). The research did not discuss the effect of geographical location 
on treatments, complications, and mortality. Stoles, McKinney, and Silliman (2014) 
found that statistical significance for increased incidents of VOC, splenic infarction, 
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ACS, and stroke was not reached for children with HbSS more than patients at sea level 
locations. The oxygen level and barometric pressure that would be 20% lower than sea 
level was not significant for increasing complications (Stoles et al., 2014). Limitations for 
the study were the exclusion of additional climate conditions and adults.   
Probst, Moore, Glover, and Samuels (2004) reported disparate conditions for rural 
locations with a 65% shortage of health care professionals in counties with predominant 
ethnic minorities. There was an African American majority in 83% of the counties. The 
effect on healthcare would entail a lack of access and a deficit in quality care. Anderson 
et al. (2014) argued that deficits in resources for SCD programs has created an 
environment of poor quality in healthcare and decreased accessibility. Studies were not 
available showing the regional characteristics in the United States for treating SCD with 
hydroxyurea as a preventive measure to decrease painful episodes and organ and tissue 
damage. In addition, regional mortality rates were not reviewed. The context of the 
geographical location studies was rural and urban locations, insurance status, and 
accessibility; the treatment standards for SCD by geographical location were not 
examined. 
Literature Search 
Walden University library database was used to search for articles by topic in 
health sciences. CINAHL and MEDLINE simultaneous search for using Boolean/ phrase 
for sickle cell disease full text. The publication dates entered were 2010 to 2015 for 
English language and scholarly (peer-reviewed) journals (839 articles). A Google Scholar 
search was done using key word sickle cell disease treatments adults since 2011 (17,800 
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results), barriers (8,130 results) and mortality (16,900 results). The majority of the 
research studies were conducted in the United States and examined genotypes, 
treatments, morbidity and mortality, emergency visits and implications, and hydroxyurea 
use. Other areas with studies on SCD included in the review were the United Kingdom, 
India, and Africa. 
Theoretical Foundation 
The Donabedian theory of quality health care (DTQHC) is a conceptual model 
proposed by Donabedian (1966) to promote and evaluate quality health care (Kobayashi 
et al., 2011) and was used as the framework for this study. The DTQHC model was 
conducive in concentrating the focus of the topic to healthcare utilization, treatments, and 
outcomes. The last revision of the model was 1987 and included a description for three 
dimensions of quality health care; providers of care, recipients of care, and health (Figure 
1) (Kobayashi et al., 2011). Sickle cell disease indicators were applied to the dimensions 
assigned in the DTQHC model. Ensuring the quality of care for patients with SCD could 











Figure 1. Donabedian theory of quality health care for Sickle Cell Disease 
The Donabedian model had not been used to assess and evaluate quality of care 
and outcomes in sickle cell disease. According to Kobayashi et al. (2011) the model was 
applied successfully to assess and evaluate patient perceptions for quality care from 
nursing staff during an inpatient hospital admission. Improvements in the quality of 
nursing care using the structure, process, and outcomes concepts validated the 
effectiveness of the Donabedian approach (Kobayashi et al., 2011). Geographical 
location, knowledge and performance of providers, and accessibility of community 
resources could affect the health of the population with chronic diseases. Utilization of 
the model creates an environment for identifying and evaluating outcomes and effects of 
the categorized indicators. The self-care management theory had been used to assess 
health outcomes in sickle cell disease and supports intervention to increase resources for 
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self-care management while improving health care outcomes (Jenerette & Murdaugh, 
2008). The Donabedian model could build upon the self-care management theory with 
the inclusion of the assessment and evaluation of provider performance which could 
affect resource distribution and self-care management.  
Literature Review 
The treatments encountered for SCD are symptomatic, preventive, and invasive. 
Pain management is needed for unpredictable episodes of VOC (symptomatic); 
hydroxyurea, and blood transfusions are preventive measures for acute and preventive 
pain management and to decrease organ damage; avoiding overexertion, maintaining 
hydration, and extreme temperatures are considered preventive; and surgical 
interventions would be invasive. Major organ damage caused by frequent painful VOC 
and hemolysis contribute to morbidity and mortality (Platt et al., 1991).  
Sickle Cell Disease Manifestations  
Sickle cell disease is a genetic inherited blood disorder. Humans have two alleles 
at each single autosomal locus; one would be inherited from each parent. In SCD, at the 
sickle cell locus there would be the predominant alleles, the A and the S. the genotype 
would be any combination of the two alleles (Ballas, S., 2011). Individuals with the AS 
genotype have sickle cell trait phenotype and the SS genotype have sickle cell disease 
phenotype (Ballas, S., 2011). Sickle cell disease has been challenging to manage because 
of the many phenomenal variations. Four genotypes of SCD have been found; HbSS, 
HbSC, Hb Sβ0 and Hb Sβ+ (Ballas, S., 2011). In addition, there are three types of pain that 
could be experienced at different levels of severity; vaso-occlusive, hemolytic, and 
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neuropathic (Niscola et al., 2011). Moreover, each type of pain could be associated with 
the type and severity of tissue and organ damage.     
Pain and pain management are considered the most prominent manifestation of 
SCD and is the number one reason for treatment of SCD patients in the emergency 
department (Odesina et al.,2010). Bergman and Diamond (2013) published that painful 
crisis was the cause of 60% of patient coming to the hospital for treatment and 90% of 
the painful episodes are treated at home. Painful events described would be unpredictable 
and severe, causing poor quality of health, excess absences from school and work, and 
early death (Neville & Panepinto, 2011). Pain frequency and severity were associated 
with causing major organ damage to the spleen, gallbladder, kidneys, brain, male 
reproductive organs, and lungs (Platt et al., 1991). Complications of SCD would lead to 
surgical removal of the organs, hemodialysis, and treatment with chronic blood 
transfusions. Precursors of painful episodes could include hypoxia, dehydration, 
overexertion, and exposure to extreme temperatures (Rogovik, Persaud, Friedman, Kirby, 
& Goldman, 2011; Smith, Coyne, Smith, & Mercier, 2003).  
Overall themes that were prevalent in the literature review of SCD included the 
medical implications of pain management, increased use of emergency services because 
of ineffective pain management, evidence based preventive treatments with hydroxyurea 
to decrease frequent episodes of pain that were not prescribed by physicians and used by 
patients, prophylactic use of blood transfusions to offset life-threatening complications, 
and mortality. Identified gaps in the literature included geographical location effect on 
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health care provider practice and performance standards in treating patients with SCD 
using evidence-based methods for pain management, hydroxyurea, and mortality rates. 
Emergency Services 
Adult sickle cell patients seek emergency care for painful episodes at higher rates 
than pediatric and adolescent patients (Tanabe et al., 2010). According to Haywood et al. 
(2013) emergency visits for SCD related conditions were over 200,000 annually in the 
United States. Vaso-occlusive crisis is the most frequent complaint given for an 
emergency department visit; 73% of pediatric patients had episodes of ACS which was 
associated with tobacco smoke in the home (Bundy, Strouse, Casella, & Miller, 2011). 
Medical and socioeconomic reasons associated with emergency visits found in the study 
were asthma, exposure to environmental tobacco smoke, and low income (Bundy et al., 
2011; Glassberg, Wang, Cohen, Richardson, & DeBaun, 2012). The reasons identified 
for increased use of emergency services are availability and the services rendered are 
accessible for healthcare despite dissatisfaction with the quality of care (Anderson et al., 
2014).  
Sickle cell patients seeking emergency care were confronted by stigmas of drug 
addiction, resulting in delayed care which could lead to life threatening complications. 
Haywood et al. (2013) published that the wait times for SCD patients in emergency 
departments was 25% longer than the general patient population rated by race, and 50% 
longer than patients with similar pain complaints from long bone fractures. Epstein et al. 
(2006) published the health care utilization of 142 sickle cell disease study participants 
and concluded that there were 54% emergency visits, 24% office visits, and inpatient 
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utilization was 20%. Tanabe et al. (2010) demonstrated the use of emergency services for 
adult SCD patients in a prospective, multisite longitudal cohort study; 155 patients with a 
median age of 32 years totaled 701 emergency visits over a 10-month period. The studies 
reviewed supported that there were increased use of emergency services by SCD patients 
for pain management; the phenomenon not investigated were the differences in 
emergency service usage based on geographic location. 
Emergency service utilization would be considered a priority option for sickle cell 
patients due to the complexities and lack of predictability of the disease. The episodes of 
painful crisis are sudden and unpredictable. In addition, home pain management regimens 
may not be sufficient during a severe episode; the average duration for a painful episode 
is 4 to 6 days (Baker & Hafner, 2012). Insufficient pain management and medical care 
could lead to increased emergency visits, life-threatening complications, and mortality.  
Treatments 
The treatments for SCD are based on counteracting the effects of VOC and 
hemolysis with pain management; opioids, hydroxyurea, and blood transfusions. Opioids 
are used during a painful crisis to decrease the duration of the episodes and improve 
quality of life (Baker & Hafner, 2012). Hydroxyurea would be prescribed to increase 
fetal hemoglobin levels and thereby decrease the frequency of painful episodes (Baker & 
Hafner, 2012). Blood transfusions are given during an acute episode of acute chest 
syndrome to dilute the sickling cells with the replacement of normal red blood cells and 
would be scheduled prophylactically to prevent future incidents (Bowers, Pepple, & Reid, 
2011). For the most part, the use of the recommended treatments for pain management 
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and preventive therapy could lead to improvements in the health outcomes of SCD 
patients. 
Pain Management   
The key source for managing SCD effectively is the prevention of frequent 
painful incidents to decrease tissue and organ damage, and mortality (Bender and Seibell, 
2014). Research has shown that increased episodes of vaso-occlusive crisis causes major 
organ damage, increasing incidents of life threatening conditions and the need for various 
surgical and medical procedures for sickle cell patients (Booker et al., 2006). A 
qualitative study, published by Maxwell, Streetly, and Bevan (1999) gave accounts of 
experiences from sickle cell patients for pain management. The findings suggested that 
pain management was deficient because of distrust among staff and patients, the 
application of stigmas of drug addiction and drug seeking, lack of control on medical 
decisions, and failure of staff to provide psychosocial support (Maxwell et al.,1999).  
Health care professionals do not believe that the patient has pain, leading to under 
treatment. Elander, Marczewska, Amos, Thomas, and Tangayi (2006) and Haywood et al. 
(2013) published that poor judgment in making pain management decisions was a 
contributory cause to inadequate treatment of pain. Aborting sickle cell pain early after 
the onset with hydration, nonsteroidal anti-inflammatory drugs (NSAIDs), narcotics, 
could lessen tissue and organ damage, and prevent ACS and PHTN (Ballas et al., 2012; 
Platt et al., 1991). Baker and Hafner (2012) published that alternatives to opioid treatment 
for pain would be the use of parenteral ketorolac (anti-inflammatory agent). The issues 
encountered with the use of anti-inflammatory agents are sickle cell pain could be 
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refractory and the need for opioids after using ketorolac for effective management would 
be delayed increasing the risks for organ damage and mortality (Baker and Hafner, 2012).  
Sickle cell pain was found to be poorly mismanaged with under treatment in a 
study by (Elander et al., 2011; Niscola et al., 2009). Recommendations have been made 
for the development of care plans and standardized treatments for SCD pain management 
to offset mismanagement of SCD pain. Ballas et al. (2012) published that the 
management of sickle cell painful crisis could decrease inflammation that would 
normally increase with recurrent episodes, decrease incidents of organ damage and 
serious complications, such as ACS, PHTN, and decrease incidents of sudden death. 
Barriers to treatments using evidence-based pain management protocols have a 
negative influence on the benefits for prescribing opioids, hydroxyurea, and the use of 
blood transfusions.  Patients with painful sickle cell crisis should be treated aggressively 
with several methods to counteract symptoms and complications (Odesina et al., 2010). 
Healthcare providers should not treat SCD symptoms by means of the traditional generic 
methods; sickle cell treatments should be based on the pathophysiology of the disease 
process (Mousa et al., 2010). Frequent episodes of VOC were associated with mortality 
as demonstrated in a cohort study of adults with SCD (Darbari et al., 2013).  Odesina et 
al. (2010) demonstrated that several therapies were needed for effective pain management 
in SCD. The results of the study were evident after the medical records were reviewed 
and showed a high use of treatment with one medication, delays in the medical 
examination, and delayed times for treatment with analgesics (Odesina et al., 2010). A 
cross-sectional survey published by Thompson and Eriator (2014) reported that 92% of 
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adults with SCD experienced pain with a duration of more than 6 months and 91% used 
alternative therapies for pain control. Adults with SCD received low quality healthcare 
because the use of evidence-based treatments was not provided (Odesina et al., 2010). It 
was published by Cain, Vang, Simone, Hebbel, and Gupta (2011) using mouse models 
that sickle cell deep tissue pain and cold sensitivity was increased with age and hypoxia; 
which could be associated with SCD adults increased use of emergency services for pain 
management. 
Opioids. Patients with SCD require large and frequent dosages of narcotic 
analgesics. Severe pain in SCD is treated with opioids and decisions for the type of drug 
and dosage should be individualized (Niscola et al., 2009). According to Delicou and 
Maragkos (2013) and Mousa et al. (2010) the standard treatment for severe pain in SCD 
was morphine. Glassberg et al. (2013) published the results of a cross-sectional survey 
which showed that the majority of emergency physicians self-reported adherence to the 
pain management standards for SCD; opioids (90%) and repeating the dose in 30 minutes 
for ineffective management (85%). Physicians with a negative attitude about SCD were 
less likely to repeat the medication in 30 minutes (20%) (Glassberg et al., 2013).  
Barriers to effective opioid use include healthcare provider hesitancy to prescribe 
dosage amounts needed to manage pain and did not trust that the patient was honest about 
the level of pain (Elander et al., 2011). Stigmas for drug addict and malingerer have been 
attached to patients with chronic nonmalignant pain that require opioids for control 
(Glassberg et al., 2013). According to Vallerand and Nowak (2010) barriers to opioid 
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therapy exists within the healthcare system and society limiting the ability of the 
individuals to access and maintenance of adequate pain management.  
Hydroxyurea. Research on the use of hydroxyurea has shown that the drug is 
safe, effective for decreasing painful episodes, and decreases organ damage and 
premature mortality in SCD (Voskaridou et al., 2010). Yet, a problem exists in not using 
the drug as a standard treatment for SCD. Preventive treatments used for sickle cell to 
decrease VOC and prevent complications from organ damage, and early mortality include 
hydroxyurea and blood transfusions (Voskaridou et al., 2010). The use of hydroxyurea as 
a treatment for SCD has been explored for greater than 25 years for safety and affect 
(Ware, 2010). It is the only treatment for SCD approved by the FDA.  
Hydroxyurea was first used as a treatment for SCD in 1984; it was found to 
decrease episodes of VOC and increase Fetal Hemoglobin (HbF) which is decreased in 
SCD patients and replaced with the mutant gene HbS (McGann & Ware, 2011). In 
addition, SCD patients are advised to remain well hydrated (drinking fluids) and avoid 
extreme weather conditions (hot, cold, and windy) (Smith et al., 2003). Hydroxyurea and 
blood transfusions are considered preventive medical treatments for adults with SCD to 
improve health and health outcomes. In any case, barriers for using hydroxyurea and 
blood transfusions could occur from misinformation and lack of knowledge. 
 Physician and patient hesitancy to comply with the use of hydroxyurea could 
arise from the controversial use for SCD since the original use of the drug was anti-
neoplastic and the long-term safety effect was not known (Ballas et al., 2013). According 
to Ware (2010), the use of hydroxyurea in young patients with SCD would be considered 
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safe; however, reports of cancer development in patients taking hydroxyurea for SCD 
have been reported. The problem with hydroxyurea would be that 59.5% of SCD patients 
self-reported never using the drug, former use was self-reported by 65.2 %, and current 
use was 52.9 % (Haywood et al., 2011). The question would be; does geographical 
location matter for increasing or decreasing the use of hydroxyurea? The reasons for 
hydroxyurea lack of use were feeling different after taking the medication, advised by the 
physician, and changes in conditions were not noted (Haywood et al., 2011; Ware, 2010).  
Medically and clinically the benefits for taking hydroxyurea for SCD would 
outweigh the risks; such as reduction of white blood count, lower bilirubin levels, and 
less hemolysis (Ballas, Singh, Adamas-Graves, & Wordell, 2013; Smith et al., 2011; 
Ware, 2010). Smith et al. (2011) published that hydroxyurea was significant in 
decreasing painful episodes, analgesic use, and visits to healthcare facilities. According to 
McGann and Ware (2011) the benefits and effectiveness of hydroxyurea treatment has 
been explored for the last 25 years and should be considered a standard treatment for 
sickle cell disease. Voskaridou et al. (2010) found that the use of hydroxyurea could 
decrease episodes of VOC and hemolysis which in turn decrease damage to major organs 
and mortality rates. In addition to ensuring appropriate treatment availability for SCD, 
dissemination of information, and education for patients and physicians would be 
beneficial.  
Blood transfusions. Blood transfusions are used for acute and chronic 
prophylactic treatment for the prevention and treatment of ACS, PHTN (Miller & 
Gladwin, 2012), stroke (Powers, Chan, Hiti, Ramilone, & Johnson, 2005), splenic 
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infarction (Owusu-Ofori & Hirst, 2013), and priapism ((Azik et al., 2012) and should be 
considered a standard treatment. The normal red blood cells are used to dilute the 
concentration of sickled cells to decrease organ damage and mortality (Owusu-Ofori & 
Hirst, 2013). Research has shown that blood transfusion should be used in the event of 
severe crisis episodes specifically when there is a previous history of ACS and PH 
(Miller & Gladwin, 2012).  
Most deaths from SCD occur in the hospital during an acute painful crisis; life-
saving treatments during these episodes would be blood transfusions (Allareddy et al., 
2014). Emergency management for severe SCD painful crisis would use blood 
transfusions to decrease incidents of premature mortality caused by anemia, 
vasculopathy, and organ damage (Vichinsky et al., 2011). Patient safety should be 
considered by health care providers by obtaining a detailed history on SCD patients to 
avoid blood transfusion complications and to make informed medical decisions for 
treatment.  
Like other treatments, the use of chronic blood transfusions could cause 
complications, alloimmunization, and iron overload (Cho & Hambleton, 2014). 
Alloimmunization occurs when the body develops antibodies against the transfused 
blood, making it difficult to provide a compatible blood match for future transfusions 
(Cho & Hambleton, 2014). Cho and Hambleton (2014) published that the benefits of 
regular blood transfusions have been associated with improving outcomes and could have 
several common side effects.  
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Transfusion reactions, iron overload, transfusion transmitted infections, and 
alloimmunization have been associated with regular blood transfusions (Detterich et al., 
2013). Sickle cell patients normally have a lower hemoglobin and hematocrit level than 
the population without SCD and sickle cell trait (Koren, Fink, Admoni, Tennenbaum-
Rakover, and Levin, 2009).  Koren et al. (2009) published that the management of the 
hemoglobin and hematocrit levels in SCD patients would involve determining the 
optimal levels for viscosity and oxygen carrying capacity, instead of attempting to 
maintain the medical textbook levels; female values equal 12 to 14 (hemoglobin) and 34 
to 36 (hematocrit) and 14 to 16 (hemoglobin) and 36 to 40 (hematocrit) for males. Sickle 
cell patients would have hemoglobin values of (±4 to 6) and hematocrits (±10) points 
lower.  Bowers et al. 2011 found that with the determination of the optimal hematocrit for 
sickle cell patients, oxygen transport could be maximized, viscosity dependent VOC 
could be reduced, and transfusion regimens could be appropriately assessed.  
Sickle cell disease patients should be involved with treatment regimens and have 
an awareness of test results, dates of testing, and optimal levels for individual 
hemoglobin and hematocrit tests to avoid transfusion complications. For this study, blood 
transfusions in the emergency setting would denote compliance with standard treatment 
regimens for patients presenting with ACS, PH, splenic infarction, priapism, and stroke. 
Above all, the literature reiterated the importance of the knowledge necessary to treat 




Symptoms related to morbid conditions increase during painful episodes and 
presenting complaints to the emergency department could originate from organ and 
vesicular damage (Glassberg et al., 2012). The common major organ damage in adults 
from frequent painful episodes would include lung damage (ACS and PHTN), brain 
infarcts (stroke), and kidney injury (Platt et al., 1994). In this section, a brief description 
is provided for the morbidities. The symptoms of chest syndrome could include fever, 
coughing, chest pain, and diagnostically a chest x-ray showing a pulmonary infiltrate 
(Miller & Gladwin, 2012). Acute chest syndrome in adults with SCD could be manifested 
from fat embolization in the bone marrow during a painful crisis, which could result in 
pulmonary emboli causing symptoms of dyspnea and chest pain, with hypoxia (Khoury et 
al., 2011). Paul, Castro, Aggarwal, and O’Neal (2011) published that acute chest 
syndrome was considered the most common reason for hospital admission related to 
symptoms and clinical findings, and death because of misdiagnosis. Pulmonary 
hypertension has been associated with hemolysis and hemolytic anemia. According to 
Miller and Gladwin (2012) PHTN occurrence is increased in adults because of chronic 
anemia, intravascular hemolysis, and increased cardiac output derived from systemic 
vascular and pulmonary damage.  
Wang et al. (2013) published that stroke occurs in 24% of sickle cell patients by 
the age of 45 years. The high incidence of stroke in adults with SCD and is associated 
with cerebral perfusion relationship to the degree of anemia (Prohovnik, Hurlet-Jensen, 
Adams, Devivo, & Pavlakis, 2009). The initiation of blood transfusions as a treatment 
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regimen could be beneficial in maintaining optimal individual hemoglobin level and 
stroke prevention (Detterich et al., 2013). Neurological symptoms such as slurred speech, 
severe headache, and visual disturbances could be reasons for seeking emergency 
treatment.  
Kidney injury in sickle cell disease could result in dialysis dependent kidney 
failure also known as end-stage renal disease, and death (Audard et al., 2014). Audard et 
al. (2014) published that ischemic injury to kidneys in sickle cell disease was a common 
occurrence during VOC. Treatments used to counteract the effects of VOC activity would 
include monitoring of intravenous hydration to correct electrolyte imbalances (Audard et 
al., 2014). 
Providers of care to sickle SCD patients ought to be aware that medications used 
to treat painful episodes and blood transfusions could be the primary source of a 
complication. Health care providers must obtain a detailed history on SCD patients to 
avoid pain management and blood transfusion complications and to make informed 
medical decisions for treatment. The literature reviewed did not explore whether 
morbidity patterns vary based on geographical location and regionally. 
Mortality 
Mortality rates for adult SCD patients increased during a study conducted from 
1979 to 2005; it was published that few children with SCD lived to adulthood and the 
median age of death was 48 years for females and 42 years for males (Platt et al., 1994). 
Bender and Seibell (2014) published that a subset of SCD patients would live to ages 
greater than 55 years, although high rates of morbidity would persist.  Contributing to the 
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increased lifespan would be decreased mortality rates in children by 3% and improved 
treatments (Bendell & Seibel, 2014). An analysis of the geographic location for 
treatments and mortality rates could provide information on the subset of SCD that have 
increased lifespans over 55 years. In addition, increased morbidities have been associated 
with premature mortality.  
Research has shown that deaths in SCD occur within three days of admission to 
the hospital with a diagnosis of SCD painful crisis (Allareddy et al., 2014). Given that 
treatment and organ damage complications could be associated with adult SCD mortality. 
Manifestations of lung damage was the origin of the two most common causes of death in 
adults with SCD HbSS from frequent VOC and hemolysis, namely acute chest syndrome 
and pulmonary hypertension (Bender & Seibell, 2014). 
Summary 
The research for SCD has focused on treatments, the effects of treatments, 
complications, and mortality. Research was lacking on how barriers to care could affect 
health outcomes, quality of life, and mortality for adults with SCD. Lack of accessibility 
to care, stigmas, and lack of knowledge for treatments could contribute to the barriers. In 
efforts to close the gap and promote effective evidence-based treatments for SCD, the 
World Health Organization (WHO) developed standards of care to be used as guidelines 
for SCD pain management (Moussavou et al., 2004). The study followed WHO standards 
and guidelines for pain management, and pain relief was experienced by 81.6% of the 
patients (Moussavou, et al., 2004). Additional pain management guidelines and protocols 
have been published for SCD to ensure quality care (Rees et al., 2003; and Ballas, Carlos, 
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& Dampier, n.d.). The standards of care could designate priorities in the management of 
SCD complications and serve as a catalyst in improving the quality of life (Yale, Nagib, 
& Guthrie, 2000). 
According to Bhagat, Baviskar, Mudey, and Goyal (2014) sickle cell patients 
reported a significantly lower health related quality of life when compared to chronically 
ill patients of non-communicable diseases. Sickle cell patients have beliefs that the 
disease could be better managed and accessibility to quality care and appropriate 
treatments could improve health outcomes and quality of life (Bhagat et al., 2014). Sickle 
Cell education could improve the prescribing of treatment regimens (physicians), and 
compliance with treatments (patients).  Several studies (Pack-Mabien & Haynes, 2009; 
Yale et al., 2000) argued that a multidisciplinary approach should be used to manage the 
care of SCD patients to increase the quality of care and improve health outcomes. The 
multidisciplinary healthcare team would include a SCD specialist, registered nurse, social 
worker, patient, and family. Yawn et al. (2014) published strong, moderate, weak, and 
consensus recommended standards of care for adults with SCD morbidities of VOC, 
ACS, stroke, renal failure, and PHTN. The strong recommendations are listed below with 
the consensus recommendations listed for acute renal failure (Yawn et al., 2014).  
• VOC: rapid treatment with opioids (intravenous route) for severe pain; 
• VOC/ ACS: use of incentive spirometer to prevent ACS during acute VOC; 
• ACS/ Stroke: blood transfusions would be used for severe episodes and 
consultation with a SCD expert;  
• ACS: intravenous cephalosporin, oxygen, and oral macrolide antibiotic; 
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• Stroke: chronic transfusion therapy program; 
• Acute Renal Failure (consensus): monitor renal function daily (creatinine levels 
and fluid intake and output), blood transfusions are not recommended, use 
hemodialysis when needed for exacerbated conditions; and 
• PHTN: obtain a diagnostic echocardiogram. 
Despite the efforts to promote quality care, only 59% of SCD have shown improvements 
in health outcomes and decreased mortality (McGann & Ware, 2011). An analysis on 
treatments, morbidity, and mortality according to geographical location could reveal 
additional barriers and deficits in care. 
Given the variations in treatment regimens, health, and health outcomes for 
patients with SCD, the effect of regional contribution was evaluated in this study. The 
methods that were used to evaluate the association of geographical location with 
emergency department usage, treatments, and mortality of adults with SCD in the United 




Chapter 3: Research Method 
Introduction 
The purpose of the study was to examine the impact of geographical location on 
the health outcomes of patients with SCD in regards to accessibility to care, treatments, 
and mortality. Accessibility to care and physician performance for treatment regimens for 
chronic diseases could vary by geographical location. Several studies (Davis et al., 1997; 
Smith et al., 2011) have shown barriers affecting the health outcomes of SCD patients 
include decreased healthcare accessibility and knowledge deficits for the use of 
hydroxyurea for treatment by providers and patients. Deductively, the literature reviewed 
reflects that the negative effects of barriers to care in SCD could cause increased 
comorbidities, decreased quality-of-life, and decreased life span.  
Chapter 3 outlines the design of the study. The sections in the chapter discuss the 
targeted population, research design, sampling and sampling procedures, and methods 
that were used to analyze the data. The reliability and validity evidence HCUP datasets, 
which is sponsored by the AHRQ, was provided along with evidence that the data was 
sufficient to respond to the research questions. 
Research Design and Rationale 
Dependent Variable(s) 
The dependent variables used for this quantitative research design included 
emergency visits and mortality rates 16 and 21 years after FDA approval of hydroxyurea 
for SCD treatment. Emergency visits for the purpose of this study indicated accessibility 
to care, disease management, and severity of disease. Hydroxyurea treatment is the only 
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drug approved by the FDA to treat SCD; in this study16 and 21 years after the approval, 
emergency visits and mortality rates were compared regionally and the results were 
considered an indicator of hydroxyurea use for disease management, severity of disease, 
and the need for accessible health care. Mortality rates were noted from inpatient hospital 
admission deaths with ICD-9 CM Codes 282.60 (SCD nonspecific), 282.61 (SCD 
without crisis), and 282.62 (SCD with crisis) listed in the medical record within the first 5 
diagnoses (Diagnosis 1, Diagnosis 2, Diagnosis 3, Diagnosis 4, or Diagnosis 5).  
Independent Variable(s) 
The four regions in the United States were considered the geographic location and 
the independent variable. An examination of the Northeast, Midwest, South, and West 
regions was conducted to analyze significant associations in the medical care and health 
outcomes of sickle cell patients.  
Covariable(s) 
Sickle cell HbSS is dominant in subSaharan African descendants, therefore the 
population in the United States included were African Americans synonymous with the 
race listed as Black reported in the NIS datasets; NEDS did not include race as a variable. 
Covariables that could affect the outcome of the dependent variables were insurance 
status, income level, age, and gender. Age encompassed adults ages 21 years and older. 
Gender of male and female along with income level, and insurance status were used to 
provide a demographic description of the population. 
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Research Design  
Correlational research. A retrospective correlational research design was used to 
examine the relationship of how living in different regions could affect the health and 
outcomes for adults with SCD. State data reported to NIS 2006 and NIS 2011 that was 
used in the study include race, gender, age in years, ICD-9-CM Codes 282.60, 282.61, 
and 282.62 diagnoses (1 through 5), in-hospital deaths, region of hospital, income level, 
and type of insurance.  
Emergency department visits and national estimates were tracked using NEDS. 
The elements that were reported by the 46 states to the NEDS 2006 and NEDS 2011 
database that were used in the study are age in years, gender, ICD-9-CM Codes 282.60, 
282.61, and 282.62, region of hospital, type of insurance, income level, and emergency 
department visits and dispositions (deaths) of patients. Researchers using the database are 
allowed to study procedures and conditions related to emergency service use. The 
independent variable (regions) and two dependent variables (ED visits and mortality) 
were analyzed for correlations with a Confidence Interval of 95% and level of 
significance of (0.05). 
The correlational study design was used to suggest possible associations between 
the independent and dependent variables. The type of association and the existence of 
extreme scores were demonstrated using bar charts to present visual representation. There 
were three dependent variables and one independent variable that was analyzed to 
determine if a significant relationship existed to contribute knowledge on how the health 
care system and health outcomes for sickle cell patients could be affected by regional 
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location. The secondary data provided an overview of SCD patients in the four regions of 
the United States for the years 2006 and 2011. The sampling method did not allow for the 
use of the cross-sectional design. Prevalence of chronic diseases is assessed from data 
collected from a defined period of time using a cross-sectional design to provide 
information on the entire population in the study. Sampling of the SCD population with a 
specific phenotype, SCD HbSS, was examined for regional differences; comparisons 
were not made between the population without SCD and the SCD population. 
Longitudinal research designs are used to compare the effects of diseases over periods of 
time. For example, SCD data would be used for the years of 2009, 2010, 2011 2012, and 
2013 to compare changes in the health outcomes during the time periods analyzed. The 
data from two time periods was used for this study which is appropriate for a 
correlational design.  
Represented in the datasets for NIS 2006, NIS 2011, NEDS 2006, and NEDS 
2011 was information collected from hospitals in 46 of the HCUP partner states and 
representative of the Northeast, Midwest, South, and West regions (Agency for 
Healthcare Research and Quality, 2012). The number of emergency visits was an 
indicator for accessibility to quality care, appropriate disease management with 
prescribed medications for home use, and health care quality would be denoted by 
decreases or increases in mortality rates across the United States among patients with 
SCD. Emergency visits have been shown to increase among adults with SCD, while there 
is a low incidence of hydroxyurea use, and the lifespan is short (Andemariam et al., 
2014). The correlational research design was used to establish the type of association 
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between the variables, denote changes in scores, determine whether the relationship is 
negative or positive, and determine the strength of the relationship. 
Healthcare Costs and Utilization Project 
The HCUP has a collection of databases with 46 participating states; the two 
databases that were used for this study are the NIS 2006, NIS 2011, NEDS 2006, and 
NEDS 2011 which included 46 states that contributed information to both databases for 
the years 2006 and 2011. The NIS database contains data on inpatient hospital 
admissions, dispositions, insurance status, and length of stay (NIS 2006 and NIS 2011). 
The NEDS has emergency department data which includes the reason for visit, diagnoses, 
and discharge disposition (NEDS 2006 and NEDS 2011). The use of NIS data estimates 
over 36 million weighted inpatient admissions, treatments, and discharge dispositions 
annually (Agency for Healthcare Research and Quality, 2013). A representation of 
special patient populations, a large sample size, uncommon treatments, and rare 
conditions are found in NIS and NEDS. The data was used to explore the relationship of 
geographical location to the number of emergency visits by sickle cell patients and 
mortality rates. The knowledge gained could influence the allocation of resources and 
dissemination of evidence-based knowledge for SCD which could reduce emergency 
services usage, improve health outcomes, and reduce health care expenditures.  
Methodology 
Target Population   
The target population included adults (21 years and older), males and females 
with SCD HbSS identified by ICD-9-CM Codes 282.60, 282.61, and 282.62, with a 
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hospital registration and discharge as an inpatient or emergency department patient. The 
targeted population varied by year and by the dataset with NIS representing the frequency 
of inpatient admits and NEDS representing the frequency of ED visits; NIS 2006 
(N=67,214), NIS 2011 (N=80,040), NEDS 2006 (N=164,698) and NEDS 2011 
(N=215,296). Regionally, frequencies for inpatient admissions and ED visits for the 
targeted population was NIS 2006; Northeast (N=17,657), Midwest (N=13,242), South 
(N=30,799) West (N=5,517), NIS 2011; Northeast (N=13,829), Midwest (N=13,663), 
South (N=36,651) West (N=6,538), NEDS 2006; Northeast (N=25,300), Midwest 
(N=23,190), South (N=98,984) West (N=17,230), NEDS 2011; Northeast (N=43,447), 
Midwest (N=25,602), South (N=122,695) West (N=13,552). The regions were 
represented by the states of Alaska, Arkansas, Arizona, California, Colorado, 
Connecticut, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, 
Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Montana, Missouri, 
Nebraska, Nevada, New Hampshire, New Jersey, New York, New Mexico, North 
Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South 
Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, and 
West Virginia, Wisconsin, and Wyoming. The number of states that contributed data to 
HCUP NIS and NEDS for the years 2006 and 2011 varied: NEDS 2006 (24), NEDS 2011 










































Figure 5. States by region for NIS 2011 
Sampling and Sampling Procedures  
A 20% sample of all United States community hospitals is approximated in the 
NIS and NEDS databases. Data for the NIS 2006 files was produced from 1,045 sampled 
hospitals (Agency for Healthcare Research and Quality, 2012). Included in the sample 
were hospitals in the Northeast (137), Midwest (299), South (415) and West (194). There 
were 1,049 hospitals in the stratified sample of NIS 2011 data containing discharge 
records. National estimates for dispositions would use the NIS 10% subsample core file 
to weight the data for the years 2006 and 2011 and statistical analysis. The number of 
sampled hospitals for the NIS 2011 data by region includes the Northeast (129), Midwest 
(306), South, (417), and West (197). The NEDS 2006 data was comprised of 955 
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hospital-based emergency departments with over 120 million weighted admits to the ED 
(Agency for Healthcare Research and Quality, 2012. There were 951 sampled hospital 
based emergency departments sampled for the NEDS 2011 database and over 131 million 
weighted ED admits. The NEDS data represents 67% of the United States population 
(Agency for Healthcare Research and Quality, 2012).  
The AHRQ used stratified random sampling, a probability sampling technique, to 
collect data for HCUP; the samples of sickle cell data are reflective of subgroups that are 
homogenous, do not overlap, the population is exclusive, and large sample sizes can be 
accommodated (Frankfort-Nachmias & Nachmias, 2008). The sample was stratified by 
region (Northeast, Midwest, South, and West), hospital ownership (profit, not-for-profit, 
public, private, government), location (rural and urban), and hospital type (teaching, 
nonteaching, trauma center. Simple random sampling was not chosen because of the large 
sample size. Systematic sampling would not allow the opportunity of equal selection of 
the population. Cluster sampling requires two stages, a sample would be selected of the 
area and a sample would be selected for the population and a true representation of the 
population would not be met (Frankfort-Nachmias & Nachmias, 2008). 
Inclusion criteria. The inclusion parameters consisted of adults in the age group 
of 21 years and over with SCD HbSS from NIS 2006, NIS 2011, NEDS 2006, and NEDS 
2011 datasets from the 46 states participating in HCUP for the years 2006 and 2011. 
First, the ICD-9-CM Codes 282 .60 (nonspecific SCD), 282.61 (SCD with crisis), and 
282.62 (SCD HbSS without crisis) were selected; next descriptive statistics followed to 
designate the frequencies for race (NIS 2006, 2011), age of 21 years and older, income 
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level, insurance status, ED visits and dispositions (deaths), inpatient admissions and 
deaths, and regions (Northeast, Midwest, South, and West).  
Exclusion criteria. Excluded from the data were patients in age groups less than 
21 years, patients that did not have ICD-9 Code 282.60, 282.61, or 282.62 listed in the 
first five diagnoses in the medical record, and states that did not report data to NIS 2006, 
NEDS 2006, NIS 2011, and NEDS 2011. After the inclusion criteria were met for the 
sample, the population was categorized into the corresponding regions (Northeast, 
Midwest, South, and West).  
Power Analysis 
Chi-Square was used to analyze the sample because the sample size was large, 
and the population in the sample had a diagnosis of SCD. For NIS datasets the patients 
that died while in the hospital were tallied and NEDS datasets were used for frequency of 
ED visits. The frequency data was used for the analysis. Cramer’s V analysis was used to 
determine the effect size NIS 2006 (.016), NIS 2011(.016), NEDS 2006 (.104), and 
NEDS 2011 (.010). Effect size was recorded as small in all four datasets which could 
occur with large sample sizes (Faul et al., 2009).  
Procedures for Recruitment, Participation, and Data Collection 
The AHRQ invites all hospitals located in the 50 states of the United States to 
participate in HCUP since 1988, and 46 states signed up as partners to participate in 
HCUP (Agency for Healthcare Research and Quality, 2012). The number of HCUP 
partner states that provide annual health care data include inpatient (46), same day 
surgery and services (34), and emergency services (32) (Agency for Healthcare Research 
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and Quality, 2012). Reporting of the data is voluntary and annual compliance with 
reporting to the databases is not consistent for all states. The choice of databases for state 
reports include the NIS, NEDS, Kids’ Inpatient Database (KID), State Inpatient 
Databases (SID), State Ambulatory Surgery and Services Database (SASD), and State 
Emergency Department Databases (SEDD) (Agency for Healthcare Research and 
Quality, 2012). 
Forty-six states entered data for NIS 2006, NIS 2011, NEDS 2006, and NEDS 
2011(Agency for Healthcare Research and Quality, 2012). The NIS is sampled from the 
SID and approximates 20% of discharges from community hospitals from the data of 
more than 7 million hospitals annually (Agency for Healthcare Research and Quality, 
2012). National trends for health care utilization, quality, outcomes, and access are 
analyzed, tracked, and identified by policymakers and researchers using NIS data 
(Agency for Healthcare Research and Quality, 2012). 
In the NIS 2006, NEDS 2006, NIS 2011, and NEDS 2011 data was collected from 
46 states that are representative of the four regions of the United States (Northeast, 
Midwest, South, and West) (Agency for Healthcare Research and Quality, 2012). The 
number of emergency visits was used as an indicator for accessibility and disease 
management. Health outcomes were determined by mortality rates. Comparisons were 
made regionally with the inclusion of mortality rates across the United States among 
patients with SCD. I used a correlational research design was to establish the association 
between the variables, denote changes in scores, determine whether the relationship was 
negative or positive, and determine the strength of the relationship. 
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Procedure for Gaining Access to Dataset 
HCUP data is sponsored by the AHRQ for the purpose of research to assist with 
public policy, improving health care quality, and as a resource to states and the federal 
government in making decisions on program development and funding (Agency for 
Healthcare Research and Quality, 2012). An application requesting the data was filed 
after completing an online tutorial on data usage and the International Review Board 
(IRB) approval. The IRB approval number assigned was 01-04-16-0351894. Permission 
was granted to use the data following the guidelines for confidentiality and protection of 
identities for individuals and establishments as outlined by the Health Insurance and 
Affordability Act of 1996 (HIPAA). The application process involved inclusion of the 
type and purpose of the research, how the data would be used, and the name and reason 
additional persons would have access to the information. The procedure for accessing the 
data required the completion of an online tutorial, filing an application and signing the 
agreement, and payment of fees to purchase the data. 
Reputability of the Sources  
The NIS datasets for the years 2004 to 2010 were used in a retrospective analysis 
by Allareddy et al. (2014) to examine acute chest syndrome as a predictor of mortality in 
adults with SCD.  A regression model analysis adjusted the effects of the independent 
variables which included sex, race, age, type of sickle cell crisis and admission, 
comorbidities, hospital characteristics, and insurance status. Sickle cell disease HbSS was 
found to be the phenotype for 84.3% of the admissions (Allareddy et al., 2014). The need 
for mechanical ventilation and acute chest syndrome predicted higher mortality rates.  
54 
 
Okam et al. (2014) published that following the approval of hydroxyurea for use 
in SCD by the Food and Drug Administration (FDA) in 1998 there was not a constant 
decline in hospital admissions using confidence interval of 95%. The study used HCUP 
datasets for NIS 1998 to 2008 in a retrospective cohort study to test the hypothesis that 
hospitalizations would decrease with the availability of hydroxyurea.  
An examination by Roghmann et al. (2013) on the likelihood of hospitalization 
contributory factors for priapism diagnoses used the HCUP NEDS data from 2006 to 
2009. A prediction of hospital admissions was made based on comorbidities, emergency 
department volume, insurance status, and hospital location. The results showed SCD 
patients (OR 2.22, p <0.001); significant for hospital admission and seeking emergency 
treatment for priapism. 
Stein, Flum, Cashy, Zhao, and McVary (2013) published study results using 
HCUP data from NEDS 2006 to 2009 datasets which examined encounters for priapism 
visits, associated diagnoses by ICD-9-CM codes, hospital characteristics, and hospital 
charges. The nationwide estimates were calculated with the established weighting of the 
sample and 21% of the patients had a diagnosis of SCD.  
Operationalization of the Variables 
The HCUP NIS 2006, NIS 2011, NEDS 2006, and NEDS 2011 datasets were 
constructed from administrative data reported for billing from participating community 
hospitals. The information collection process begins with the initial admission to the 
hospital as an in-patient or emergency department visits and contains ICD-9-CM codes, 
Current Procedure Terminology (CPT) codes, Clinical Modification (CM) coding for 
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comorbidities, and disposition. Data collection for NIS 2006 and NIS 2011, NEDS 2006, 
and NEDS 2011 occurred 16 and 21 years after the approval of hydroxyurea and was 
used to compare the number of emergency visits and mortality rates.  
For this study, a data file was created from NIS 2006 and NIS 2011 datasets for 
inpatient admission records and deaths of patients with the diagnoses codes 282.60, 
282.61, and 282.62 listed within the first five diagnoses, regions, 21 years and older, 
income level, gender, and insurance status. Data files were created from NEDS 2006 and 
NEDS 2011 datasets for emergency visits and ED dispositions with data that included 
diagnoses codes 282.60, 282.61, and 282.62 listed within the first five diagnoses, regions, 
21 years and older, income level, gender, and insurance status. Hospital location (region) 
identifiers were used to designate geographical location and ascertain regional location. 
There were not any outliers identified in the data. The main predictor variables for the 
study were regional location (Northeast, Midwest, South, and West); the outcomes 
included the number of emergency visits and mortality rates for the years 2006 and 2011. 
Covariates that could affect the outcomes existed with age, gender, insurance status, and 
income level and were explored using descriptive statistics to assess variations and 
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The number of emergency visits could be an indicator for accessibility to health care, 
disease management was recognized with emergency visits, and health outcomes were 
acknowledged with mortality.  
Data Analysis Plan 
Standard quality control procedures exercised by HCUP for age and date of birth, 
admission, discharge, and ICD-9-CM codes include confirmation that the data is valid, 
consistent internally, and when feasible consistent with norms (Agency for Healthcare 
Research and Quality, 2012). Inconsistent and questionable values are labeled with C or 
negative 6-filled. The inconsistent values are not changed or fixed; special missing values 
labels are assigned to preserve the anomalies for the researcher to investigate (Agency for 
Healthcare Research and Quality, 2012). Edit failures are tabulated and used to assess the 
quality for each data source. Quality review is conducted by an independent contractor 
annually to verify all numerical and categorical data elements, frequency distributions, 
and cross-frequencies (Agency for Healthcare Research and Quality, 2012). Procedures 
for automated quality control are used to assess the validity of values; numeric data 
verified as numeric, ranges checked against norms, maximum allowed values checked 
against data ranges, and diagnostic and procedure codes verified against norms (Agency 
for Healthcare Research and Quality, 2012).  Internal consistency is assessed to capture 
inconsistencies, such as birthdates that would be inconsistent with the documented age. 
Edit checks are performed on HCUP data annually since 1998; the edit check numbers 
are assigned with a description and the action taken (Agency for Healthcare Research and 
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Quality, 2012). Missing values were eliminated in this study because the variables that 
were selected from the dataset had less than five percent missing values. 
Data Cleaning Procedures 
Statistical Program for Social Sciences (SPSS), Stata Data Analysis and Statistical 
Software for Professionals, and Statistical Analysis Software (SAS) are compatible with 
HCUP datasets; SPSS was used in this study for statistical analysis. The data was 
provided on CD-ROMs, downloaded, unzipped, and saved in folders on the (C) drive of 
the PC. The HCUP datasets were downloaded to SPSS using the SPSS load files that 
were provided by HCUP.  
The data was converted to SPSS, reviewed, and cleaned in stages. First the 
variables were examined and there were not any errors detected. Next values were added 
to the variables according to the HCUP values that were assigned in the codebook. Then, 
frequencies were checked and compared to the summary statistics provided on the 
H.CUPnet web page to ensure the datasets were downloaded correctly, the statistics were 
accurate, and to ensure the reliability and validity of the research (Field, 2013). The data 
was screened for missing data, blank entries, typing errors, coding errors, and misfiled 
data elements.  
The data was cleaned so the same results could be obtained when applied to a 
similar situation. In addition, valid data would measure the concepts intended. The last 
step was the selection and coding of the variables that would be used for this study. 
Variables that were recoded were age by birthdate 0-124 years (21 years plus) and the 
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first five diagnoses (DX primary, DX1, DX2, DX 3, DX4) were auto recoded using SPSS 
for ICD-9-CM Codes 282.60, 282.61, and 282.62. 
Research Questions and Hypotheses 
I used descriptive statistics and frequencies to define the targeted SCD population 
in the areas of insurance status, income level, age, and gender. Regression was not used 
for statistical analysis because the assumptions for homoscedasticity were not met and the 
results would be biased. Chi-Square analysis was used to assess if there was a significant 
association between the effect of regions on insurance status, age, gender, income level, 
emergency visits, and mortality (dependent variables) and regions (independent) variable. 
The research questions that were explored in the present study using HCUP data from 
NIS 2006, NIS 2011, NEDS 2006, and NEDS 2011 include 
RQ1: Is there a significant association between emergency services use 
(accessibility) among adults with SCD and regional geographic location (Northeast, 
Midwest, South, and West)?  
H01: There is no significant association between emergency services use 
(accessibility) and the regional geographical location (Northeast, Midwest, South, and 
West) represented by 46 states in the United States from the HCUP database in adults 
with SCD.  
Ha1: There is a significant association between emergency services use 
(accessibility) and the regional geographical location (Northeast, Midwest, South, and 
West) represented by 46 states in the United States from the HCUP database in adults 
with SCD.  
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Data Analysis Plan. Chi-Square was the analysis used to explore if there was a 
significant association of the dependent variables (emergency visits) as an indicator of 
accessibility to health care as the geographic regions Northeast, Midwest, South, and 
West (independent variables) change. 
RQ2: Is there an association between the number of emergency department visits 
(disease management) for adults with SCD in the four regions (Northeast, Midwest, 
South, and West) 16 and 21 years after FDA approval of hydroxyurea for SCD 
treatment? 
H02: There is no significant association in the number of emergency department 
visits (disease management) for adults with SCD in the four regions (Northeast, Midwest, 
South, and West) 16 and 21 years after FDA approval of hydroxyurea for SCD treatment. 
Ha2: There is a significant association in the number of emergency department 
visits (disease management) for adults with SCD in the four regions (Northeast, Midwest, 
South, and West) 16 and 21 years after FDA approval of hydroxyurea for SCD treatment. 
Data Analysis Plan. Chi-Square was the analysis used to explore if there was a 
significant association of the dependent variables (emergency visits) an indicator for 
disease management as the geographic regions Northeast, Midwest, South, and West 
(independent variables) change. The significance of the association was shown for the 
number of emergency visits and mortality rates in accordance to each region and the 
strength of the relationship.  
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RQ 3:  Is there an association between hydroxyurea approval and SCD mortality 
rates in adults in relation to geographic location (Northeast, Midwest, South, and West) in 
2006 (16 years later) and 2011 (21 years later)? 
H03: Hydroxyurea approval does not have a significant association on mortality 
rates in adults with SCD in relation to geographic location (Northeast, Midwest, South, 
and West) in 2006 (16 years later) and 2011 (21 years later)? 
 Ha3: Hydroxyurea approval has a significant association on mortality rates in 
adults with SCD in relation to geographic location (Northeast, Midwest, South, and 
West) in 2006 (16 years later) and 2011 (21 years later)? 
Data Analysis Plan. Chi-Square analysis was used to statistically examine if 
there was a significant association regionally for deaths rates among SCD patients. The 
regional geographical locations in the Northeast, Midwest, South, and West (independent 
variable) and the effect on the mortality rates (dependent variable) were compared 
numerically.  
Threats to Validity 
Threats to external validity from the use of secondary data would include the 
accurateness and completeness of the information provided by the participating states. 
Limitations could be applied by specific states as to how the data could be used and the 
information in the dataset could be eliminated. Internal validity could be compromised 
with data input errors and coding. Threats to statistical conclusion validity were avoided 
by choosing a valid sampling method and meeting the assumptions of the statistical tests 
used increased the validity of the results. Threats to validity in HCUP datasets were 
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addressed using edit procedures and were described in the procedures, recruitment, and 
data collection section. The editing process is annual and conducted prior to release of 
datasets to counteract the effects of threats to internal and external validity. 
Ethical Procedures 
An online HCUP data use tutorial and application were filed acknowledging the 
privacy and confidentiality of using the datasets with existing private records or 
documents. The agreement to access the HCUP datasets involved compliance with 
HIPAA guidelines for privacy and confidentiality of the patients and the institutions. The 
data has HCUP encrypted coding to protect the identity (Agency for Healthcare Research 
and Quality, 2012). Coding that identifies the institution was eliminated from the dataset. 
Once the data was received, the targeted population was recoded by diagnosis using the 
auto recode function in SPSS. Location was identifiable by regional geographic location 
(Northeast, Midwest, South, and North without the input of zip codes. In addition, the 
data was stored in a file on a password locked home computer that is used solely by the 
researcher. According to publications of the Office of Research and Integrity, U.S. 
Department of Health and Human Services, data storage does not have a time and amount 
limitation for storage, unless the research is funded and the researcher must allow for the 
storage requirements of the funding institution. The HCUP billing and discharge data that 
was used for this study will be destroyed using a software produce such as, Eraser or 
CyberScrub after five years of maintenance.  
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According to the guidelines from Walden University (2010A), the Walden 
University IRB application was filed and approved requesting permission to conduct the 
research. The information requested on the application included a description of the  
• proposed research,  
• research stakeholders and partners,  
• benefits of the research,  
• potential risks and conflict of interest,  
• confidentiality and data integrity,  
• tools used for data collection, and  
• a description of the study participants.  
The Potential Risk and Benefits form in the IRB application described opportunities for 
disclosure that could compromise privacy, confidentiality, and cause unintended effects 
to others. The goal of the review board was to ensure that Walden University is in 
compliance with Federal regulations and university ethical standards (Walden University, 
2010A).  
Summary 
Chapter 3 provided a description of the targeted population, datasets, research 
design, and instrumentation that were used to examine the research questions with 
reliability and validity. In addition, ethical concerns, confidentiality, and privacy have 
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been acknowledged. A numerical description of the population was used along with a 
quantitative retrospective method in a comparative study to describe the association 
between the variables with statistical analysis. The retrospective correlational design 
required a review of the literature for the identification of variables that could affect 
outcomes in SCD, in order to identify outcomes and their relationship to the changes.  
The goal was to explore whether the independent variable has influenced the dependent 
variables and the effects of covariates on the outcomes. The approach used to address the 
research questions involved the use of dependent and independent variables, and 
covariables to describe the correlation of geographic locations to emergency department 
visits (accessibility and disease management), and mortality using HCUP data. In 














Chapter 4: Results 
Introduction 
The purpose of this research study stood to compare the effects of geographic 
locations regionally, emergency department visits, and deaths from SCD using Chi 
Square. The statistical analyses explored the relationship between the independent 
variable (regions) and dependent variables (ED visits and mortality). The targeted 
population was adults age 21 years plus with SCD HbSS in the United States. In previous 
research barriers to care for SCD patients have been identified in the areas of 
accessibility, disease management, stigmas, and quality of care (Anderson et al., 2014; 
Brousseau et al., 2010; Haywood et al., 2013; Smith et al., 2011; Ware, 2010). NIS 2006, 
NIS 2011, NEDS 2006, and NEDS 2011 HCUP, AHRQ datasets were used to explore 
regional differences in health care and health outcomes for sickle cell patients at 16 and 
21 years after the approval of hydroxyurea for treatment. 
Chapter 4 provides a description of the population characteristics by region for the 
targeted sample. Statistical analyses were used to determine the association of regions, 
ED visits, and mortality, and answer the research questions. Decisions were made to 
reject or accept the null hypotheses based on those findings. The research questions and 
hypotheses that were used to guide the study included: 
RQ1: Is there a significant association between emergency services use 
(accessibility) among adults with SCD and regional geographic location (Northeast, 




H01: There is not a significant association between emergency services use 
(accessibility) and the regional geographical location (Northeast, Midwest, South, and 
West) represented by 46 states in the United States from the HCUP database in adults 
with SCD.  
Ha1: There is a significant association between emergency services use 
(accessibility) and the regional geographical location (Northeast, Midwest, South, and 
West) represented by 46 states in the United States from the HCUP database in adults 
with SCD.  
RQ2: Is there an association between the number of emergency department visits 
(disease management) for adults with SCD in the four regions (Northeast, Midwest, 
South, and West) 16 and 21 years after FDA approval of hydroxyurea for SCD 
treatment? 
H02: There is no significant association in the number of emergency department 
visits (disease management) for adults with SCD in the four regions (Northeast, Midwest, 
South, and West) 16 and 21 years after FDA approval of hydroxyurea for SCD treatment. 
Ha2: There is a significant association in the number of emergency department 
visits (disease management) for adults with SCD in the four regions (Northeast, Midwest, 
South, and West) 16 and 21 years after FDA approval of hydroxyurea for SCD treatment. 
RQ3: Is there an association between hydroxyurea approval and SCD mortality 
rates in adults in relation to geographic location (Northeast, Midwest, South, and West) in 
2006 (16 years later) and 2011 (21 years later)? 
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H03: Hydroxyurea approval does not have a significant association on mortality 
rates in adults with SCD in relation to geographic location (Northeast, Midwest, South, 
and West) in 2006 (16 years later) and 2011 (21 years later). 
Ha3: Hydroxyurea approval has a significant association on mortality rates in 
adults with SCD in relation to geographic location (Northeast, Midwest, South, and 
West) in 2006 (16 years later) and 2011 (21 years later). 
Data Collection 
The datasets for the research were obtained from HCUP, AHRQ after Walden 
IRB approval. Health Care Utilization Project collects administrative data annually from 
participating partners and the data used for this study was collected from January 1, 2006 
to December 31, 2006 and January 1, 2011 to December 31, 2011. The steps for 
obtaining the datasets and the methods used by HCUP to collect data were discussed in 
Chapter 3. The dataset for NIS has over 8 million cases and NEDS represents over 27 
million cases. The cases from the datasets that met the inclusion criteria for this study 
were weighted to make national estimates and included NIS 2006 (N=67,214), NIS 2011 
(N=80,040), NEDS 2006 (N=164,698), and NEDS 2011(N=215,296). The variables were 
selected from the datasets as demonstrated in Chapter 3, Figure 3.  
Discrepancies in Data Collection 
During the course of the analysis phases, there were changes made to the research 




• Race was eliminated in the NEDS files by HCUP because of nonreports of race 
by the states that followed regulatory mandates; race was reported in the NIS files 
and used in the study to describe the population. NIS 2011 showed that 93.9% of 
patients diagnosed with SCD HbSS were African American (Table 5). 
• Black was used to describe the race for people of subSaharan African descent in 
the HCUP data files, for this study African American has been used instead of 
black. 
• In order to encompass the majority of sickle cell HbSS cases, the diagnosis codes 
used in the study were expanded to include 282.60 (nonspecific sickle cell 
anemia) which is used when the genotype is not known, 282.61 sickle cell anemia 
HbSS without crisis, and 282.62 (sickle cell anemia HbSS with crisis); 
• The number of medical record recorded diagnoses was expanded from using only 
the primary and secondary diagnoses (diagnoses 1and 2), to include diagnoses 1 
through 5. This change was made to capture the diagnosis of SCD from the billing 
invoices when other medical and surgical conditions received billing priority, 
such as pneumonia or a cholecystectomy. 
 Descriptive and Demographic Characteristics 
The population sizes for the research were presented in four datasets, NEDS 2006, 
NEDS 2011, NIS 2006 and NIS 2011 files, containing the subgroup of sickle cell patients 
selected for this research. Included was the age group of 21 plus years with diagnoses 1 
through 5 with the ICD-9-CM Code of 282.60 (nonspecific sickle cell anemia), 282.61 
(HbSS sickle cell anemia without crisis), and (282.62 HbSS sickle cell anemia with 
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crisis). Statistical analyses were performed on the SCD subgroup to describe the 
population. The descriptive and demographic characteristics are shown in Table 2, Table 
3, Table 4, and Table 5. The NEDS datasets were used to measure ED visits and NIS 
datasets were used to measure inpatient hospital admissions. All data were weighted for 
analyses with the application of discharge weights provided in the datasets to predict 
national estimates.  
The weighted sample size generated from HCUP data files allowed for 
generalizability of the observed ED visits nationally. The inclusive population weighted 
sample size for NEDS 2006 N=164,698 (Table 2), and NEDS 2011 N=215,296 (Table 3). 
The largest SCD sample population was represented in the NEDS 2011 dataset. The 
sample was comprised of 42% males and 58% females with 47% from the low income 
quartile. Medicare and Medicaid were identified as the primary insurance for 35% and 
42%, respectively. Regionally, 45% of the population lived in the South (Table 3). The 










NEDS 2006 Sample Descriptive Demographic Characteristics (weighted) 




Gender               100.0 .56 .497 
Male 73,201 44.4   
Female 91,497 55.6   
Race (not reported)     
Median Household Income  100.0 1.81 .976 
$1-$35,999 81,381 48.0   
$36,000-$44,999 42,172 21.0   
$45,000-$58,999 24,545 19.8   
$59,000+ 13,403 11.2   
Hospital Region  100.0 2.66 .861 
Northeast 25,300 15.4   
Midwest 23,190 14.1   
South 98,984 60.1   
West 17,230 10.5   
Expected Primary Payer  99.8 2.11 1.043 
Medicare 49,218 29.9   
Medicaid 72,195 43.8   
Private 25,413 15.4   
Self-pay 13,886 8.4   
No charge 1,046 .6   
Other 2,557 1.6   
Disposition from Emergency Department  100.0 .56 .497 
Did not die 157,375 99.8   
Died in ED 49 .0   
 




















NEDS 2011 Sample Descriptive Demographic Characteristics (weighted) 




Gender               100.0 .001 .497 
Male 33,492 41.8   
Female 46,549 58.2   
Race (not reported)     
Median Household Income  100.0 1.81 .976 
$1-$38,999 99,917 46.4   
$39,000-$47,999 52,266 24.3   
$48,000-$62,999 38,651 18.0   
$63,000+ 18,907 8.8   
Hospital Region  100.0 3.00 .912 
Northeast 43,447 20.2   
Midwest 35,602 16.5   
South 122,695 57.0   
West 13,552 6.3   
Expected Primary Payer  99.8 1.98 1.017 
Medicare 70,262 35.2   
Medicaid 91,877 42.1   
Private 30,884 16.0   
Self-pay 17,574 4.2   
No charge 763 .3   
Other 3,427 2.0   
Disposition from Emergency Department  100.0 .56 .497 
Did not die 215,254 99.8   
Died in ED 41 .0   
 
NEDS 2011 TOTAL N= 215,296     
 
The weighted sample size generated from the HCUP data files allows for 
generalizability of the observations nationally. The inclusive population weighted sample 
size for NIS 2006 was (N=67,214) [Table 4] and NIS 2011 (N=80,040) [Table 5] for 
inpatient hospital admissions, representing 67% of the sickle cell anemia HbSS 
population nationally. The largest sample size was the NIS 2011 data comprised of 42% 
males and 58% females, with 48% from the low income quartile. Medicare and Medicaid 
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were identified as the primary insurance for 35% and 42% of the population. Regionally, 
46% of the population lived in the South (Table 5). 
Table 4 
NIS 2006 Sample (weighted) descriptive demographic characteristics 
Variable n=Frequency Valid 
Percent 
Mean Standard  
Deviation 
Gender        100.0 .58 .493 
Male 28,166 41.9   
Female 38,987 58.1   
Race  100.0   
White 806 1.6   
Black 46,205 68.7   
Hispanic 1,835 2.7   
Asian or Pacific Islander 48 .1   
Native American 41 .1   
Other 675 1.0   
Median Household Income  100.0 1.87 1.018 
$1-$35,999 32,208 49.3   
$36,000-$44,999 15,882 24.3   
$45,000-$58,999 10,810 16.5   
$59,000+ 6,469 9.9   
Hospital Region  100.0   
Northeast 17,657 26.3   
Midwest 13,242 19.7   
South 30,799 45.8   
West 5,517 8.2   
Expected Primary Payer   2.07 1.081 
Medicare 21,614 32.2   
Medicaid 28,659 42.6   
Private 11,584 17.2   
Self-pay 2,964 4.4   
No charge 536 .8   
Other 1,805 2.7   
Disposition from Hospital  100.0 .01 .078 
Did not die 66,777 99.4   
Died 416 .6   
     








NIS 2011 Sample (weighted) Descriptive Demographic Characteristics 




Gender               100.0 .58 .493 
Male 33,492 41.8   
Female 46549 58.2   
Race  100.0 2.11 .630 
White 936 1.3   
Black 70,511 93.9   
Hispanic 1,773 2.4   
Asian or Pacific Islander 192 .3   
Native American 27 .0   
Other 1,682 2.2   
Median Household Income  97.7 1.94 1.059 
$1-$38,999 37,560 48.0   
$39,000-$47,999 16,453 21.0   
$48,000-$62,999 15,517 19.8   
$63,000+ 8,753 11.2   
Hospital Region  100.0 2.213 1.175 
Northeast 13,829 26.3   
Midwest 13,663 19.7   
South 36,651 45.8   
West 6,538 8.2   
Expected Primary Payer  99.8 1.98 1.017 
Medicare 28,185 35.2   
Medicaid 33,698 42.1   
Private 12,849 16.0   
Self-pay 3,396 4.2   
No charge 214 .3   
Other 1,637 2.0   
Disposition from Hospital  100.0 .00 .065 
Did not die 79,683 99.6   
Died 336 .4   
 
NIS 2011 N = 80,040     
 
The variables hospital disposition (dependent) and hospital region (independent) 
did not meet the assumptions for the proposed regression analysis for normality and 
homoscedasticity. Homoscedasticity was evaluated with the Levene’s test (p < .001). The 
variances were not equal across the sample. The sample met the assumptions for Chi-
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Square analysis. The dependent and independent variable were categorical and were 
measured at a nominal level. The dependent and independent variables consisted of two 
or more categories. 
Results 
Chi-Square analysis was used to determine the relationship between hospital 
region (independent) and ED visits and mortality (dependent) variables. The assumptions 
that were met included the variables were categorical and consisted of two or more 
categorical independent groups. The predetermined confidence interval was 95% and p 
value was <0.05 for the statistical analysis. The NEDS 2006 and NEDS 2011 datasets 
were analyzed to respond to research questions number 1and 2. The NIS 2006 and NIS 
2011 datasets were analyzed to answer research question number 3. 
Research Question 1 
RQ1:  Is there a significant association between emergency services use 
(accessibility) among adults with SCD and regional geographic location (Northeast, 
Midwest, South, and West)?  
H01: There is no significant association between emergency services use  
(Accessibility) and the regional geographical location (Northeast, Midwest, South, and 
West) represented by 46 states in the United States from the HCUP database in adults 
with SCD.  
Ha1: There is a significant association between emergency services 
use(accessibility) and the regional geographical location (Northeast, Midwest, South, and 
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West) represented by 46 states in the United States from the HCUP database in adults 
with SCD.  
The NEDS 2006 with a sample size of N=164,704 was significant for an 
association between regions and emergency services use Pearson chi-square x (21) = 
5331.293, p =. 000 (Table 6, Figure 6). The strength of the association was weak; Phi 
(.180), p = .000 and Cramer’s (.104), p = .000 (Table 7). The NEDS 2011 with a sample 
size of N= 215,132 was significant for an association between regions and emergency 
services use Pearson chi-square x (3) 44.502, p =. 000 (Table 6, Figure 6). The strength 
of the association was weak; Phi (.014), p = .000 and Cramer’s (.010), p = .000 (Table 7). 
Research Question 2 
RQ2: Is there an association between the number of emergency department visits 
(disease management) for adults with SCD in the four regions (Northeast, Midwest, 
South, and West) 16 and 21 years after FDA approval of hydroxyurea for SCD 
treatment? 
H02: There is no significant association in the number of emergency department 
visits (disease management) for adults with SCD in the four regions (Northeast, Midwest, 
South, and West) 16 and 21 years after FDA approval of hydroxyurea for SCD treatment. 
Ha2: There is a significant association in the number of emergency department 
visits (disease management) for adults with SCD in the four regions (Northeast, Midwest, 
South, and West) 16 and 21 years after FDA approval of hydroxyurea for SCD treatment. 
The NEDS 2006 data was significant for an association between regions and 
emergency services use Pearson chi-square x (21), = 5331.293, p = .000 (Table 6, Figure 
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6). The strength of the association was weak; Phi (.180), p = .000 and Cramer’s (.104), p 
= .000 (Table 7). The NEDS 2011 data was significant for an association between regions 
and emergency services use Pearson chi-square x (3) 44.502, p = .000 (Table 6, Figure 6). 
The strength of the association was weak; Phi (.014), p = .000 and Cramer’s (.010), p = 
.000 (Table 7). 
Table 6 
NEDS 2006, NEDS 2011 Chi-Square Tests 








Pearson Chi-Square 5331.392 21 .000 
Likelihood Ratio 6876.872 21 .000 
Linear-by-Linear Association 903.557 1 .000 
N of Valid Cases 164,704   









Pearson Chi-Square 44.502 3 .001 
Likelihood Ratio 41.671 3 .001 










NEDS 2006 and NEDS 2011 Chi-Square Symmetric Measures (weighted) 
NEDS 2006  Value Approximate Significance 
  
Nominal by Nominal  Phi .180 .000 
 Cramer’s V .104 .000 
N of Valid Cases  164,704  
NEDS 2011  Value Approximate Significance 
  
Nominal by Nominal  Phi .014 .000 
 Cramer’s V .010 .000 
N of Valid Cases  215,132  
 
 
Northeast Midwest South West
NEDS 2006 15% 14% 60% 11%










Figure 6. NEDS 2006 and NEDS 2011 Chi-Square significant association for emergency 








Research Question 3 
RQ 3:  Is there an association between hydroxyurea approval and SCD mortality 
rates in adults in relation to geographic location (Northeast, Midwest, South, and West) in 
2006 (16 years later) and 2011 (21 years later)? 
H03: Hydroxyurea approval does not have a significant association on mortality 
rates in adults with SCD in relation to geographic location (Northeast, Midwest, South, 
and West) in 2006 (16 years later) and 2011 (21 years later)? 
Ha3: Hydroxyurea approval has a significant association on mortality rates in 
adults with SCD in relation to geographic location (Northeast, Midwest, South, and 
West) in 2006 (16 years later) and 2011 (21 years later)? 
There was significant association between mortality and geographic location for 
patients with SCD for NIS 2006 data. Pearson chi-square x (3), N= 17.866, p = .000 
(Table 8, Figure 7). The strength of the association was weak; Phi and Cramer’s V N= 
67,193 (.016), p = .000 (Table 9). The association between mortality and hospital regions 
was significant in the data from NIS 2011 with Pearson chi-square x (4), N= 20.663, p = 
.000 (Table 8, Figure 7). The strength of the association was weak; Phi and Cramer’s V 






NIS 2006, NIS 2011 Chi-Square Tests (weighted) 








Pearson Chi-Square 17.866 3 .000 
Likelihood Ratio 17.889 3 .000 
Linear-by-Linear Association 5.643 1 .018 












Pearson Chi-Square 20.663 4 .000 
Likelihood Ratio 19.892 4 .001 
Linear-by-Linear Association 7.242 1 .007 
N of Valid Cases 80,019   
 
Table 9 
NIS 2006 and NIS 2011 Chi-Square Symmetric Measures (weighted) 
NIS 2006  Value Approximate Significance 
  
Nominal by Nominal  Phi .016 .000 
 Cramer’s V .016 .000 
N of Valid Cases  67,193  
NIS 2011  Value Approximate Significance 
  
Nominal by Nominal  Phi .016 .000 
 Cramer’s V .016 .000 








Northeast Midwest South West
NIS 2006 14% 9% 35% 4%












Figure 7. NIS 2006 and NIS 2011 Chi-Square significant association for inpatient 
dispositions by region, died in hospital 
 
Summary 
I designed the study to explore the effects of geographical regions on the health of 
sickle cell anemia patients 16 and 21 years after the approval of hydroxyurea by the FDA 
for treatment. Inpatient deaths and ED visits were used as indicators to document changes 
in health and health outcomes. The NEDS 2006, NEDS 2011, NIS 2006, and NIS 2011 
datasets were tested separately with Chi-Square. The results revealed a significant 
association between ED visits (dependent variable), deaths (dependent variable), and 
regions (independent variable). The associations were weak according to Phi and Cramer 
results. ED visits increased in the Northeast (N=43,447), Midwest (N=35,603), and South 
(N=122,695), when compared to 2006 when ED visits in the Northeast were (N=25,300), 
Midwest (N=23,190), and South (N=98,984) [Table 10]. The West showed a decrease in 
ED visits shows a summary of inpatient deaths and emergency department visits by 
region results for are in 2011 (N=13,552) and 2006 showed an increase (N=17,230) 
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[Table 10]. The Northeast, Midwest, South, and West had more deaths in 2006 than 
2011.  
Table 10 
NIS 2006, NIS 2011, NED 2006, and NEDS 2011 Summary of inpatient deaths and 
emergency department visits by region 
  Northeast Midwest South West 
NEDS 2006 ED Visits 25,300 23,190 98,984 17,230 
NEDS 2011 ED Visits 43,447 35,602 122,695 13,552 
NIS 2006 Inpatient Deaths 93 62 233 28 
NIS 2011 Inpatient Deaths 62 37 152 24 
 
The results for the research questions are 
• RQ1: There was a significant association between ED visits (accessibility) and 
geographic regions in the United States. 
• RQ2: There was a significant association between ED visits (disease 
management) and geographic regions in the United States. 
• RQ3: There were decreased mortality rates in the four regions of the United 
States (Northeast, Midwest, South, and West) 13 years after the FDA approved 
Hydroxyurea for treatment. 
Relative to the findings revealed in Chapter 4, Chapter 5 includes a 
discussion of the future research, relevance of the findings, limitations of the study, 
and the social change that could occur to improve the health and health outcomes of 




Chapter 5: Discussion 
Introduction 
This study was used to document the effects of geographical locations on the 
health and health outcomes of SCD patients, 21 years and older, 16 and 21 years after 
FDA approval of hydroxyurea for the treatment of the disease. The findings of the study 
are important because hydroxyurea is the only drug approved by the FDA as a preventive 
measure to counteract the effects of SCD. Hydroxyurea increases and improves the 
ability of the body to produce fetal hemoglobin which is decreased or nonexistent for 
sickle cell patients (McGann & Ware, 2011). The increased production of fetal 
hemoglobin decreases the sickling of the red blood cells, thereby decreasing painful 
episodes, organ damage, and increases the life span (McGann & Ware, 2011). Medically, 
it is recommended that hydroxyurea should be a standard of care for patients with SCD 
by WHO and the NHLBI (Moussavou et al., 2004). 
Emergency visits and inpatient hospital deaths were measured regionally with 
HCUP datasets; NEDS 2006 and NEDS 2011 were used to document accessibility and 
disease management (emergency visits) regionally and NIS 2006 and NIS 2011 were 
used for health outcomes (deaths) regionally. The results for the years were compared to 
document regional changes that could indicate accessibility and disease management. 
The findings using Chi-Square analysis showed that the relationship between regions, 
emergency department visits, and deaths was significant. Phi and Cramer’s revealed that 
the strength of the relationships was weak.  
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The association between ED visits (accessibility and disease management) and 
regions was discovered in RQ1 and RQ2 in this study and was significant based on Chi-
Square results. RQ3 disclosed a significant association between deaths and regions using 
Chi-Square.  
Interpretation of Findings 
Increased frequency of emergency visits found in this study were consistent with 
previous studies by (Brousseau et al., 2010; Wolfson et al., 2012) showing patients with 
SCD with high rates of emergency department visits (accessibility to care and disease 
management). Regionally emergency department visits increased from 2006 to 2011 with 
the NEDS datasets, except the West showed a decrease (Table 11). 
Table 11 
ED Visits 2006 and 2011 
 ED Visits 2006 ED Visits 2011 
Northeast 25,300 43,447 
Midwest 23,190 35,602 
South 98,984 122,695 
West 17,230 13,552 
 
The availability and accessibility of care were the reasons identified that sickle cell 
patients seek care in emergency departments (Bundy et al., 2011; Glassberg et al., 2012; 
Haywood et al., 2013). Pain management was found to be the primary reason sickle cell 
patients sought care in the emergency department (Tanabe et al., 2010). The alternate 
hypotheses for this study were supported for Research Questions 1 and 2; there is a 
significant association between emergency visits (accessibility and disease management) 
and regional location (Northeast, Midwest, South, and West) in the United States. 
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Mortality rates for sickle cell patients showed regional decreases in this study from 2006 
to 2011(Table 12). 
Table 12 
NIS Recorded Deaths  
 Deaths 2006 Deaths 2011 
Northeast 93 62 
Midwest 62 37 
South 233 152 
West 28 24 
 
According to a publication by Bender and Seibell (2014), ages 55 years and older would 
be the life expectation for a subset SCD patients and high rates of morbidity would 
persist. Platt et al. (1994) reported that the median age of death was 42 years (males) and 
48 years (females). The number of sickle cell deaths by region, which was not found in 
previous research, was explored in this study; age at the time of death was not examined. 
The alternate hypothesis was supported in the findings; there was a significant association 
with SCD mortality rates and the four regions in the United States 16 and 21 years after 
the approval of hydroxyurea.  
Limitations of the Study 
The study population for generalization was limited to adults 21 years and older 
with SCD (nonspecific 282.60), HbSS (without crisis 282.61), and HbSS (with crisis 
282.62) by ICD-9-CM Codes. The analysis was performed 16 and 21 years after the 
approval of hydroxyurea in 1990 by the FDA, however, the consumption of hydroxyurea 
was not measured. The results of the study provide an overall view of the adult sickle cell 
population in terms of emergency visits (accessibility and disease management) and 
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mortality (health outcomes) by region for the years 2006 and 2011. Limitations would be 
the information reported and restrictions on data use that was applied by specific states; 
the information could have been eliminated in the dataset, such as race, and the number 
of incidents per region could not be reported if the frequency was 10 or less. Internal 
validity could be compromised with data input errors and coding. 
Recommendations 
Sickle cell patients 21 years and older with HbSS, the most severe genotype that 
is predominate among people of subSaharan African descent living in the United States 
that used emergency services in 2011 were:  
• Low income (46.4%) (Table 3).  
• Insured by Medicaid (42.1%) (Table 3). 
• Lived in the Southern region of the United States (57%) (Table 3).  
There were differences in the emergency visits and deaths among the regions, the South 
had the highest rates in emergency visits; South (122,695), Northeast (43,447), Midwest 
(35,602), and West (13,552). Future research could focus on the Southern region of the 
United States to explore disease management and accessibility to care. Increased 
emergency visits could be reduced with the implementation of standardized treatment 
regimens for SCD patients, thereby reducing the costs for frequent emergency visits for 
treatments (Andemariam et al., 2014; Epstein et al., 2006; Hague & Telfair, 2000; Kauf 
et al., 2009; Wolfson et al., 2012). 
Comparatively, the mortality rates in 2011 were higher in the South (152) than the 
Northeast (62), Midwest (37), and West (24). Mortality may possibly be investigated 
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further to explore the age groups, treatment regimens, and whether there was an increase 
or decrease in morbidities for adults with SCD. Additional future research could 
document the age of death for males and females with SCD HbSS phenotype, and note if 
there is an increase in life span for 43 years (males) and 48 years (females), with the 
inclusion of the role of hydroxyurea in the sample population. 
Implications 
An indicator for accessibility, disease management, and severity of disease is the 
frequency of sickle cell patients seeking care in emergency departments Bergman & 
Diamond, 2013; Haywood et al., 2013). The effect on accessibility and disease 
management could be initiated by a lack of continuity of care from private physicians. 
Accessibility to care is affected by insurance coverage; the majority of patients have 
government funded insurance (Medicaid) which is not widely accepted by private 
physicians because of the low payment fees (Brousseau et al, 2010; Jan et al., 2013; 
Wolfson et al., 2012). Providers of healthcare could be educated on the Sickle Cell 
Treatment Act of 2003-2004 which provides for matched funding on treatment costs of 
Medicaid covered SCD patients (108th Congress 1st Session, 2004). Education on a 
chronic disease self-management care model could benefit SCD improvements in disease 
management and health outcomes regionally (Jenerette & Murdaugh, 2008). The 
socioecological model was the framework used to integrate the effects of internal and 
external factors on the health and health outcomes of sickle cell patients. Factors that 
would require consideration for education and treatments would be income level, 
insurance status, and the incorporation of the region where the patients reside. 
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The concepts of the Donabedian model for quality in healthcare used with the 
guidelines of a chronic disease self-care management model could be effective in 
improving health outcomes and quality of care for sickle cell patients. Providers of care 
would communicate with patients in regards to laboratory tests values and discuss 
treatment regimen decisions collaboratively. A chronic disease self-care management 
model specific for SCD would include patient awareness of norms for individual 
hemoglobin and hematocrit levels, date of last blood transfusion, routine medications, 
surgical and medical history, and effective pain management regimen. The elements of 
SCD self-care management can contribute to the concepts of providers of care and health 
outcomes in the Donabedian model for quality health care. Educating providers and 
patients would be beneficial in introducing a chronic disease self-care management 
model and contribute to the effectiveness of the process.  
Improvements in education and increased SCD awareness would be the initial 
steps needed for social change to occur and benefit advances in disease management, 
health care, and health outcomes. Social change implications could involve the creation 
of a group of SCD patients with better quality health and quality of life.  The changes 
would increase the probability of progress academically and in the workforce.  
Future research might include a discussion on qualitative and mixed methods to 
explore the use of hydroxyurea by the adult population and the development of education 
for health care professionals and sickle cell patients. The results of this study could lead 
to improving education in collaboration with a SCD chronic disease self-care 
management model for health care providers, patients, families, and medical 
88 
 
organizations. Demographically the majority of the sickle cell population congregated in 
the South with a majority in low income quartiles, and high rates of government issued 
insurance. The Southern region had increased deaths and ED visits that exceeded the 
other regions and could be the alpha site to target an educational program. The National 
Sickle Cell Disease Act of 1972 provides funding to disseminate educational materials 
for provider and patient education, and grants for research on controlling and treating the 
disease (American Society of Hematology, 2008).  
Conclusion 
Since SCD was discovered over 100 years ago, treatment regimens have been 
geared toward symptoms caused by the condition; opioids for pain management, blood 
transfusions for severe sickling and painful crisis, surgical interventions to remove 
damaged organs, and hemodialysis to replenish renal function for damaged kidneys. 
Since 1990, hydroxyurea is the only drug approved by the FDA for preventive treatment, 
yet research has shown that it is not widely prescribed by physicians or used by patients. 
Increased frequency of emergency department visits demonstrated in this study indicate a 
need for improvements in disease management. There were decreased frequencies in 
death rates in the results that should be investigated further concerning comorbidities and 
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